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Toll-like receptors (TLRs) play a crucial role in the recognition of pathogen-derived components as a 
first line of defense against infections. TLR4 and TLR2 receptors play a key role due to their cell 
surface location and their ability to identify a diversified spectrum of pathogen components. The early 
signaling activation via TLR4 and TLR2 receptors was studied and the results presented in the first 
chapter of this work show that TLR2 ligands activated NF-κB and MAPKs earlier and exhibited a 
higher IL-10 /IL-12 ratio at later time points compared to TLR4 ligands. The results further show the 
involvement of the phosphatase MKP-1 in the control of the MAPK p38 activation and that MKP-1 
contributes to pro-inflammatory cytokine’s upregulation. Furthermore, p38 is critical for IL-10 
expression in response to TLR2 ligands, which triggers the macrophage change to a M2 and regulatory 
phenotype in contrast to the M1 phenotype induced by TLR4 activation. Therefore, the early TLR2-
mediated p38 induction contributes for the high IL-10 production as a virulence strategy to suppress 
host Th1 response against certain types of pathogens. 
TLR2 activation induces type I interferon expression mediated by MyD88 and TRIF signaling 
pathways. The role of TRIF-IFN-β-signaling in TLR2-mediated inflammatory responses was 
investigated and the results presented in the second chapter indicate that TLR2 ligands induce IFN-β 
expression, dependent of receptor endocytosis which consequently activate the interferon transcription 
factors IRF3 and IRF7. TRIF signaling was found to be required for IFN-β induction and consequent 
expression of the cytokine IL-12 in response to TLR2 ligands. Moreover, TLR2 is determinant for 
Listeria monocytogenes recognition, however, modifications of this bacteria cell wall avoid its 
recognition. The in vivo administration of TLR2 ligands in a murine model of neonatal listeriosis 
showed lower levels of bacterial load in neonate’s microglia, and Listeria-infected dendritic cells 
stimulated with TLR2 ligands presented higher levels of protective TNF-α and IL-12 cytokines, 
mediated by IFN-β. Therefore, TLR2 ligands exert a modulatory effect on cytokines with beneficial 
effects on the prevention of Listeria dissemination. This data points to TLR2 ligands as potential 
adjuvants in vaccine models for this bacterial infection.  
TLR4 is considered the major receptor to recognize all LPSs. However, some atypical LPS’s structures 
depart from the well-studied E. coli LPS and induce a TLR2-dependent inflammatory response in 
immune cells. The results in the third chapter demonstrate that the atypical LPS from Ochrobactrum 
intermedium is a TLR4/TLR2 agonist, inducing a weaker inflammatory response compared to E. coli 
LPS. Molecular docking analysis of O. intermedium LPS predicts a favorable formation of a 
TLR2/TLR4/MD-2 heterodimer, further confirmed by FRET. These imply that atypical LPSs may 








Los receptores “Toll-like” (TLRs) tienen un papel clave en el reconocimiento de compuestos derivados 
de patógenos siendo una primera barrera contra las infecciones. TLR4 y TLR2 son importantes debido 
a su localización en la superficie celular y por su capacidad de reconocer una variad de moléculas 
derivadas de patógenos. Se estudió la señalización temprana por la activación de TLR4 y TLR2 fue y 
los resultados presentados en el capítulo 1 de este trabajo demuestran que ligandos de TLR2 activan 
NF-κB y MAPKs más tempranamente y exhiben un ratio IL-10/IL-12 más alto que los ligandos TLR4. 
Además, la fosfatasa MKP-1 controla la fosforilación de p38 y contribuye al incremento de citoquinas 
proinflamatorias. Nuestros resultados indican que p38 es importante para la expresión de IL-10 en 
respuesta a ligandos de TLR2, lo que induce un cambio del fenotipo de los macrófagos a tipo M2 y 
regulatorio, en lugar del tipo M1 que es inducido por la activación de TLR4. Por lo tanto, la activación 
temprana de p38 mediada por TLR2 contribuye para la alta producción de IL-10 como una estrategia 
de virulencia para suprimir la respuesta Th1 del hospedero contra determinados patógenos. 
La activación de TLR2 induce la expresión de interferón tipo I mediado por la señalización dependiente 
de MyD88 y TRIF.  El papel de la señalización TRIF-IFN-β en la respuesta inflamatoria inducida por 
TLR2 fue estudiado y los resultados descritos en el capítulo 2 indican que la activación de TLR2 lleva 
a una producción de IFN-β, dependiente de la internalización del receptor, lo que activa los factores de 
trascripción de interferón IRF3 y IRF7. La señalización por TRIF es necesaria para la inducir IFN-β y 
la citoquina IL-12 por la activación de TLR2. Además, TLR2 es importante para el reconocimiento de 
Listeria monocytogenes, sin embargo, modificaciones en la pared de esta bacteria evitan su 
reconocimiento inmunológico. La administración in vivo de ligandos TLR2 en un modelo murino de 
listeriosis neonatal disminuye la carga bacteriana en la microglía de los neonatos y su tratamiento en 
células dendríticas infectadas incrementa los niveles de TNF-α y IL-12, mediado por IFN-β. Por lo 
tanto, los ligandos TLR2 tienen un efecto modulador en los niveles de citoquinas y previenen la 
diseminación de la bacteria. Esto apoya el uso de ligandos TLR2 como potenciales adyuvantes en 
modelos de vacunas para esta bacteria.  
TLR4 es conocido como el receptor de reconocimiento a los lipopolisacáridos (LPS). Sin embargo, 
algunos LPSs presentan una estructura distinta del bien estudiado LPS de E. coli y inducen respuestas 
inflamatorias dependientes de TLR2. Los resultados del capítulo 3 demuestran que el LPS de 
Ochrobactrum intermedium es un agonista TLR4/TLR2 y induce una respuesta inflamatoria más débil 
que el LPS de E. coli. Estudios de modelado molecular predicen que el O. intermedium LPS favorece 
la formación del heterodímero TLR2/TLR4/MD-2, que se confirmó por FRET. Esto indica que estos 






















The living organisms have evolved defense strategies by the immune system in order to combat the 
invading microbial pathogens. The immune system is classically divided into innate and adaptive 
systems. The innate immune system provides a first line of defense against a broad spectrum of 
pathogens.  
Adaptive immunity confers a slower but more specific response, consisting in clonal expansion of 
antigen-specific cells that combat the infection and provide immunological memory.  
1.1 Pattern recognition receptors  
Macrophages, dendritic cells and neutrophils provide a first line of defense against many common 
microorganisms and are essential for the control of common bacterial and viral infections (Akira and 
Takeda, 2004b). These cells are able to discriminate between “self” and pathogens through the function 
of pattern recognition receptors (PRRs). PPRs can sense a pathogen infection  by recognizing 
conserved pathogen-associated molecular patterns (PAMPs) (Charles A. Janeway, 2002). PRR-
mediated recognition of pathogens by phagocytes triggers the degradation of invading pathogens by 
their engulfment, digestion and killing, followed by initiation of a cascade of inflammatory responses. 
It is now evident that PRRs also recognize noninfectious components that can cause tissue damage and 
endogenous molecules that are released during cellular injury, often termed as damage-associated 
molecular patterns (DAMPs) (Matzinger, 1994). Examples of DAMPs are the associated protein high-
mobility group box 1(HMGB1), heat shock proteins (HSPs), purine metabolites derived from necrotic 
cells, as well as extracellular matrix fragments such as hyaluronan and biglycan generated by 
proteolytic enzymes from damaged cells. These endogenous stress signals once released play a similar 
role as PAMPs regarding their ability to activate inflammatory signaling pathways.  
To date, four classes of PRRs families have been identified and characterized. These families consist 
of cytosolic PRRs such as the (NOD)-like receptors (NLRs) and RIG-I-like receptors (RLRs), as well 
as transmembrane proteins such as the Toll like receptors (TLRs) and C-type lectin receptors (CLRs). 
The RLR family consists of RNA helicases that detect viral double-stranded RNA. Activation of RLRs 
induce an antiviral response through the recruitment of the adapter protein IFN-β promoter stimulator 
(IPS)-1, the activation of the transcription factors interferon regulatory factor IRF3 and NF-κB, and 
subsequent induction of type I IFN. The NLR family consists of more than 20 members, and several 
respond to the various PAMPs, non-PAMP particles and cellular stresses. Upon recognition of ligands, 
this receptors trigger the production of pro-inflammatory cytokines, including the activation of the 






1.2 Toll-like receptors 
Charles Janeway predicted in 1989 the existence of innate immunity PRRs able to recognize microbial 
products and link innate and adaptive immunity.  
The discovery of TLRs began in the 1980s with the identification of the protein receptor IL-1R1. IL-1 
is a pro inflammatory cytokine and it was reported to be an essential mediator of host defense 
(Dinarello, 1991) In 1991, the IL-1R1 cytosolic domain sequence was shown to be  homologous to the 
cytosolic domain of a protein termed Toll, found in Drosophila melanogaster. Toll protein was initially 
identified as a gene product essential for the development of embryonic dorsoventral polarity in 
Drosophila. Subsequent studies showed that Toll was an important receptor for host defense against 
fungal infection in flies, which only have innate immunity (Lemaitre et al., 1996).   
In 1997, the first human homolog of the Toll receptor was cloned (now termed TLR4) and showed the 
induction of gene’s expression involved in inflammatory response (Medzhitov et al., 1997). In the next 
two years, a loss-of-function mutation of the mouse homologue of hToll was identified in a mouse 
strain that is unresponsive to lipopolysaccharide, revealing hToll as the signaling receptor for the 
bacterial LPS(Hoshino et al., 1999). Shizuo Akira and colleagues, who generated multiple TLR and 
adaptor molecule-knockout mice, have later contributed considerably to revealing the functions of the 
other TLRs and which specific ligands are recognized by each TLR (Akira and Takeda, 2004a; Shizuo 
Akira, 2006). 
1.3 Macrophage phenotypes: host defense, wound healing and immune regulation 
The recognition of microbes by TLRs is thought to follow a model, in which immune cells use different 
TLRs to detect several PAMPs, from different classes of microbes, simultaneously. This elicits 
different responses that are required to efficiently combat the pathogens present in the host (Underhill 
and Ozinsky, 2002). Triggering TLRs with distinct PAMPs induce the release of different patterns of 
cytokines and chemokines by macrophages, which drive these cells to assume different phenotypes 
and functions. Basically, macrophages can polarize in three distinct phenotypes (Sica and Mantovani, 
2012). Microbial products such as LPS and pro-inflammatory cytokines (IFN-γ, TNF) confer a M1 
type macrophage, that have enhanced microbicidal and capacity to secrete high levels of IL-12, IL-6, 
IL-23, TNF-α, iNOS and ROS species. M2-type macrophages are induced by signals such as 
glucocorticoids, DAMPs, IL-4, IL-13, and IL-10 and even by helminths-derived PAMPs. This class of 
macrophages is involved in parasite containment and promotion of tissue repair, through induction of 
arginase 1, IL-10 and PPRγ. The third class, termed regulatory macrophages have an anti-inflammatory 
activity. Two stimuli are needed to induce IL-10 production, for example, prostaglandins, 





macrophages can also downregulate IL-12 production. Therefore, IL-10/IL-12 can be used to define 
these class of macrophages. 
1.4 TLR family 
TLRs are expressed in many cell types, including macrophages, DCs, B cells, some types of T cells 
and even in non-immune cells such as fibroblasts, epithelial and endothelial cells.  The expression of 
these receptors is dynamic, changing rapidly in response to pathogens, DAMPs and environmental 
stresses. The TLRs are type I transmembrane proteins, and due to the considerable homology in the 
cytoplasmic region, they are members of a larger superfamily that includes the interleukin-1 receptors. 
TLRs are composed of three major regions: the cytoplasmic, transmembrane and extracellular domain 
(Fig. I1). These structures belong to the leucine-rich repeat (LRR) family and form characteristic, 
horseshoe-like structures. As the cytoplasmic domain of TLRs shows high homology to that of the IL-
1 receptor family, this domain is termed as Toll/IL-1 receptor (TIR) domain. The extracellular domain 
of TLRs contains 16 to 28 tandem copies of a consensus sequence leucine-rich repeat (LRR modules). 
This motifs mediate the recognition of PAMPs (Bell et al., 2003). 
 
 
So far, 10 TLR family members have been identified in humans and 12 in mice, with TLR1–TLR9 
being conserved in both species. TLR10 is expressed in humans but not in mice because of a stop 
codon in the murine TLR10 gene. TLR11, TLR12 and TLR13 have been lost from the human genome. 
Toll-like receptors play a central role in detecting all types of pathogens, including viruses, bacteria, 
and parasites. Moreover, TLRs are localized in various cellular compartments. More specifically, 
TLR1,2,4,5, and 6 are mainly found in the cell plasma membrane, where they can recognize “first 
contact” PAMPs from bacteria, fungi and parasites. TLR3, 7, 8 and 9 are sequestered in the ER in 
resting cells and rapidly traffic to endolysosomes in response to nucleic acids components from viruses 
and bacteria (Fig. I2) (Shizuo Akira, 2006). The proper distribution of TLRs in different cellular 
Fig. I1 TLR structure. The intracellular TIR domain is 
composed of ∼200 amino acids in length, and the regions of 
homology comprise three conserved boxes, which are required 
for initiating downstream signaling pathways. The extracellular 
domain harbors tandem copies of LRR. These modules include 
highly conserved segment, LxxLxLxxNxL, in which "L" is Leu, 
Ile, Val, or Phe and "N" is Asn, Thr, Ser, or Cys and "x" is any 
amino acid. LRRs have a secondary structure composed of a beta 
strand and an alpha helix connected by a looped segment (Akira 





compartments facilitates ligand accessibility for downstream signal transduction, and the endosomal 
localization of nuclei-acid-sensing TLRs allows the discrimination between self from non-self-nucleic 
acids. 
 
1.4.1 TLR2 subfamily 
TLR1, TLR2, TLR6 and TLR 10 are commonly categorized into the TLR2 subfamily due to the amino 
acid sequence similarities and chromosomal localization. Phylogenetic analysis reveals that TLR10 is 
most related to TLR1 and TLR6, both of which mediate immune responses to a variety of microbial 
and fungal components in cooperation with TLR2. This receptor binds a wider array of ligands than 
any other member of the TLR family. These include lipopeptides, lipoteichoic acid from Gram-positive 
bacteria, lipoarabinomannan from mycobacteria, zymosan from fungi, tGPI-mucin from Trypanosoma 
cruzi and the hemagglutinin protein from measles virus (Shizuo Akira, 2006). TLR2 initiates immune 
Fig.I2 TLR signaling and trafficking.  





responses by recognizing diacylated and triacylated lipopeptides and the discrimination of the lipid 
portion of lipoproteins is controlled by whether TLR2 heterodimerizes with TLR1 or TLR6. 
Specifically, the TLR2/TLR1 heterodimer recognizes triacylated lipopeptides, whereas the 
TLR2/TLR6 heterodimer recognizes diacylated lipopeptides. In addition, TLR2-deficient (TLR2-/-) 
mice, which were found to be highly susceptible to challenge with Staphylococcus aureus or 
Streptococcus pneumoniae demonstrating the importance of TLR2 in the host defense against Gram-
positive bacteria (Echchannaoui et al., 2002). Besides infectious diseases, TLR2 is also implicated in 
pathologic conditions such as rheumatoid arthritis, ischemia/ reperfusion injury, and allergy (O'Neill 
et al., 2009).  
TLR10 is the only family member without a defined agonist or function, however recent studies have 
shown that TLR10 share some agonists with TLR1 like Pam3CSK4. Similar to TLR1 and TLR6, 
TLR10 also requires heterodimerization with TLR2 for the recognition of these agonists as well as 
microbial and fungi components. Nevertheless, TLR10 is not able to activate the downstream signaling 
mediators that are commonly associated with the TLR1 or TLR6 members (Guan et al., 2010). It is 
reported that hTLR10 transgenic mice exposed to TLR2 ligands produce fewer cytokines in vivo. 
TLR10 functions as an inhibitory receptor, exerting a modulatory effect in the TLR2-mediated 
cytokine production (Oosting et al., 2014). Indeed, TLR10 is the only member of the TLR family 
described so far as an inhibitory receptor.  
TLR2 has been shown to functionally collaborate with other types of receptors such as dectin-1, a lectin 
family receptor that recognizes the fungal cell wall component β-glucan and zymosan, inducing its 
internalization. Moreover, TLR2 can interact with other co-receptors on the cell surface that assist 
PAMP recognition. These include CD36, which enhances immune responses to some TLR2/TLR6 
ligands. The co-receptor CD14 is involved in the recognition of diacylated lipopeptide and 
lipoarabinomannan. (Gantner et al., 2003; Hoebe et al., 2005). 
1.4.2 TLR4 
TLR4 was the first TLR identified and was characterized as an LPS receptor through studies of two 
mouse strains, C3H/HeJ strain and C57BL/10ScCr that were nonresponsive to LPS. LPS, is a major 
constituent of the outer membrane of Gram-negative bacteria and is mostly present with six acyl chains, 
like E. coli LPS, which is one of the most potent agonists of the human innate immune system. LPS 
consists of three distinct domains: the lipid A composed by fatty acid chains linked to a disaccharide 
backbone; a core saccharide and the O-antigen that render LPS solubility. The core can be composed 
of up to 15 sugars and be identified as inner and outer core. Inner core is less variable, usually formed 
by 3-deoxy-d-manno-oct-ulosonic acid (KDO) sugars. In contrast, the outer core is more variable since 





the bacterium strain. The O-antigen is the hydrophilic region of the LPS and strain-specific. It is usually 
composed of up to 50 repeating oligosaccharide units, with different kinds of monosaccharides, 
projected from the core towards the exterior of the bacterial surface (Silipo and Molinaro, 2010).  
Accessory molecules such as LBP, CD14 are involved in LPS signaling, enhancing the TLR4 
sensitivity to recognize LPS in minute concentrations (Haziot et al., 1996). LBP, which belongs to the 
lipid-binding/lipid transfer protein family, forms a high-affinity complex with LPS that is subsequently 
delivered to CD14. CD14 is present in the plasma membrane on myeloid cells or in a soluble form in 
the serum. It contains a hydrophobic pocket that comprises LPS FA chains.  This protein delivers LPS 
to MD-2, a co-receptor associated with TLR4. In basal conditions, TLR4-MD-2 complex exist as 
monomers in the cell membrane. When LPS binds to MD-2, it induces the interaction of two monomers 
forming a TLR4/MD-2/TLR4*/MD-2* homodimer. This interaction promotes the dimerization of the 
intracellular domains, which leads to the activation of downstream signaling pathways and final 
immune response. It has been described that TLR4 is in constant translocation between Golgi complex 
and the cell surface to replenish its levels at the cell surface TLR4 for LPS recognition (Latz et al., 
2002). In order to be transported to the surface, TLR4 needs to be glycosylated (Nagai et al., 2002). 
Alternatively, TLR4 can be translocated to endosomal compartments capable of recognizing 
phagocytosed bacteria. Upon receptor activation at the surface, the receptor is endocytosed, and 
activates TRIF signaling (Fig. I2). Endosomes mature into late endosomes and fuse with lysosomes 
where the receptor is degraded.  
1.4.3 TLR9 subfamily 
TLR7, TLR8 and TLR9 constitute the TLR9 subfamily, due to their high gene homology to each other. 
These receptors recognize nucleic acids derived from viruses and bacteria, as well as endogenous 
nucleic acids in pathological conditions. The activation of these receptors occurs by trafficking from 
the ER to the endolysosomes, where proteolytical cleavage generates functionally competent receptors. 
Thus, viral nucleic acids are efficiently recognized in these compartments, avoiding the activation by 
self-nucleic acids. TLR7 recognizes ssRNA derived from viruses such as vesicular stomatitis virus, 
influenza A and HIV-1 genomic RNA as well as from the host (Diebold et al., 2004). TLR7 also detects 
RNAs from bacteria such as Group B Streptococcus in endolysosomes in conventional DCs (cDCs) 
(Mancuso et al., 2009). TLR8 is phylogenetically more similar to TLR7 and recognizes viral ssRNA, 
however, although it is expressed in mice, it appears to be nonfunctional (Heil et al., 2004). TLR9 
senses CpG DNA motifs from bacterial DNA and viral dsDNA such as herpes simplex virus (HSV) 







TLR3 recognizes genomic RNA purified from dsRNA viruses such as reovirus and dsRNA produced 
during the course of replication of single-stranded RNA (ssRNA) viruses such as RSV, 
encephalomyocarditis virus (EMCV) and West Nile virus (Alexopoulou et al., 2001; Wang et al., 
2004). TLR3 triggers immune responses by producing type I IFN and inflammatory cytokines to 
prevent viral spread. TLR3 also recognizes viral dsRNA synthetic analog polyI:C. Noteworthy, the 
recognition mechanism of nucleic acids by TLR3 was clarified by solving and analyzing the crystal 
structure of hTLR3 ectodomain (Bell et al., 2005; Choe et al., 2005; Liu et al., 2008). The horseshoe-
like shape of the receptor comprises a large surface area to facilitate dsRNA recognition. The ligand 
binds to the N-terminal and C-terminal portions of TLR3 ectodomain stabilizing the formation of a 
TLR3 homodimer. TLR3 deficiency in humans is associated with susceptibility to herpes simplex virus 
(HSV)-1 and TLR3-deficient mice are susceptible to infection with murine cytomegalovirus (MCMV) 
(Tabeta et al., 2004; Zhang et al., 2007). TLR3 is present in conventional DCs, macrophages as well 
as in epithelial cells. 
1.4.5 TLR5 
TLR5 recognizes flagellin, the major constituent of bacteria flagella and is a potent activator of innate 
immune responses. TLR5 is highly expressed on the basolateral surface of intestinal epithelial cells, 
sensing the invasion of flagellated bacteria in the gut. In addition, TLR5 is highly expressed in lamina 
propria DCs (LPDCs), in the small intestine. Specifically, in the presence of flagellin, LPDCs induce 
the differentiation of naïve B cells into IgA-producing plasma cells and promote the differentiation of 
naïve T cells into Th17 and Th1 cells (Uematsu et al., 2008). Moreover, lamina propria DCs can 
produce retinoic acid that contribute for these humoral and cellular responses. Thus, LPDCs plays a 
critical role in regulating both innate and adaptive immune response in the intestine through TLR5. 
Moreover, TLR5 is present in lung epithelial cells, protecting the respiratory tract from flagellated 
bacteria. Indeed, a polymorphism in the ligand binding site of TLR5 compromises the TLR5-driven 
signaling and is associated with susceptibility to pneumonia, caused by L. pneumophila, a flagellated 
bacterium  (Hawn et al., 2003). Thus, these findings indicate the important role of TLR5 in microbial 
recognition at the mucosal surface. 
1.4.6 TLR11, 12, 13 subfamily 
TLR11 is present in mice but not in humans and is localized in endolysosomes and is highly expressed 





deficient mice that were susceptible to the infection with these bacteria (Zhang et al., 2004). TLR11 
also recognizes profilin-like molecule derived from the intracellular protozoan Toxoplasma gondii, 
which functions as an actin-binding protein, implicated in the parasite mobility and/or invasion 
(Yarovinsky et al., 2005). These findings show a role for this receptor in host recognition of protozoan 
pathogens.   
TLR12 is an intracellular TLR and it was found to also recognize Toxoplasma’s profilin, similar to 
TLR11. However, the levels of expression of each TLR differ in tissues. TLR12 expression is restricted 
to myeloid cells, macrophages, and lymphoid cells. TLR11 is more expressed at epithelial surfaces, 
though it can also be expressed in macrophages and DCs. TLR12 and TLR11 were found to 
heterodimerize in response to Toxoplasma gondii in mice to induce an optimal response towards the 
parasite (Andrade et al., 2013). 
TLR13 is also an intracellular receptor, localized in the endolysosomes. It was identified a bacterial 
23S ribosomal RNA (rRNA) sequence as a ligand for TLR13 (Hidmark et al., 2012; Oldenburg et al., 
2012). TLR13 may be important for the detection of specific viruses since is able to recognize the 
vesicular stomatitis virus to activate innate immune antiviral responses (Shi et al., 2011).  
1.5 Classical TLR signaling pathways 
The interaction of TLRs with their ligands trigger the activation of signaling pathways, by promoting 
the dimerization of TLRs or by altering the conformation of existing dimers. This ligand-receptor 
engagement leads to the induction of inflammatory cytokines and type I IFNs for host defense. TLR 
signaling begins with the recruitment of different TIR-domain containing adaptor molecules such as 
MyD88, TRIF, Mal (TIRAP) and TRAM that will interact with the receptor TIR domains. Mal and 
TRAM adaptors bridge MyD88 and TRIF to the TIR to facilitate downstream signaling (Oshiumi et 
al., 2003; Yamamoto et al., 2002) (Fig. I2). MyD88 is recruited by all TLRs except TLR3 and initiate 
the MyD88-dependent signaling with activation of the transcription factor NF-κB and mitogen-
activated protein kinases (MAPKs) to induce inflammatory cytokines in macrophages and dendritic 
cells. In addition to MyD88, TLR4 and TLR2 subfamily recruits TIRAP adaptor for MyD88-dependent 
signaling initiation but not TLR5 nor TLR 7-9 subfamily. Particularly, TLR7 and TLR9 only recruit 
MyD88 adaptor to induce type I IFNs via IRF7 and IRF1 transcription factors. On the other hand, TRIF 
is used by TLR4 and TLR3, initiating the TRIF-dependent cascade which activates NF-κB and IRF3 
for the induction of inflammatory cytokines and type I IFNs (Shizuo Akira, 2006). Unlike TLR3, TLR4 
recruits TRIF through TRAM mediated by endocytosis, and it has been considered the only TLR 
capable of activating both MyD88 and TRIF-dependent signaling pathways (Kagan et al., 2008). 
However, recent publications report that TLR2 can also recruit TRAM/TRIF and induce IFN-β in 





1.5.1 MyD88-dependent signaling pathway 
MyD88 adaptor is important to link TLRs with the downstream signaling molecules. After association 
with receptor complex, MyD88 recruits and activates the kinase IRAK4. IRAK1 and IRAK2 are 
sequentially recruited and activated by phosphorylation forming a complex that subsequently interacts 
with TRAF6. This enzyme forms a complex with E2 ubiquitin-conjugating enzymes Ubc13 and Uev1A 
to catalyze the formation of lysine63-linked polyubiquitin chains. These chains activate the complex 
TAK1 that then activates the IKK complex. NF-κB inhibitory protein, IkBα is consequently 
phosphorylated and undergoes degradation by the ubiquitin-proteasome system, allowing nuclear 
translocation of NF-κB and binding to the promoters of target genes. TAK1, can simultaneously 
phosphorylate the MAPKKs MEK1/MEK2, MEK3/MEK6 and MEK4/MEK7 to phosphorylate 
MAPKs ERK1/2, p38 and JNK respectively. Besides the MAP3K TAK1, the activation of ERK1 and 
ERK2 is mediated by the upstream kinase TPL2 (Arthur and Ley, 2013).MAPKs are important for the 
induction of transcription factors such as cyclic AMP-responsive element-binding protein (CREB) and 
activator protein 1 (AP1) to promote the transcription of inflammatory cytokines genes (Akira, 2010).  
1.5.2 TRIF-dependent signaling pathway 
TRIF-dependent signaling activation leads to induction of NF-κB and IRFs. TRIF recruits TRAF6 and 
RIP1 to activate TAK1 via mechanisms similar to those in the MyD88-dependent pathway. However, 
TRIF interacts with RIP1 and undergoes K63-linked polyubiquitination. RIP1 also interacts with 
TRADD, and this multiprotein complex is required for NF-ҡB activation. Moreover, TRIF can also 
recruit TRAF3, which activates the noncanonical IKKs TBK1 and IKKi that induce IRF3 and IRF7 
activation. Phosphorylated IRFs translocate to the nucleus and initiate the transcription of type I 
interferons (Fig. I2) (Akira, 2010). IRF3 and IRF7 share the greatest structural homology and have 
gained much attention as the key regulators of type I IFN gene expression induced by viruses. IRF3 is 
constitutively expressed and resides in the cytosol in the latent form in resting cells. Upon TLR 
activation, IRF3 is phosphorylated at Ser396, 398, 402, 404, and 405 in site 2 of the C-terminal 
regulatory region, which alleviates auto-inhibition and causes IRF3 nuclear translocation. Once in the 
nucleus, IRF3 is phosphorylated at site 1 (Ser385 or Ser386), which is required for IRF3 dimerization. 
IRF3 can form dimers with itself or with IRF7. These complexes bind to the promoters of type I IFN 
genes to facilitate their expression. Unlike IRF3, IRF7 is expressed in low amounts in unstimulated 
cells and is strongly induced upon stimulation. IRF7 can form a homo or heterodimers with IRF3 and 
each can differentially activate type I IFN. IRF3 activates more IFN-β, whereas IRF7 can activate 
efficiently both IFN-α and IFN-β genes (Honda et al., 2006). Once activated, IRF7 induces the type I 





1.6 Regulation of MAPKs: role of dual-specificity protein phosphatases 
The phosphorylation state of MAPKs is controlled, among others, by dual-specificity protein 
phosphatases (DUSPs, also known as MKPs), which dephosphorylate both the threonine and tyrosine 
residues in the activation loop of MAPKs, thereby inactivating them. MKPs contain a highly conserved 
C-terminal catalytic domain and a less conserved N-terminal region that engages the substrate. Three 
major phosphatase subfamilies are classified according with their sequence similarity, substrate 
specificity and subcellular localization. The subfamily formed by MKP-1 (DUSP-1), PAC-1 (DUSP2), 
MKP-2 (DUSP4) and HVH3 (DUSP5) is primarily localized in the nuclear compartment and encoded 
by immediate-early genes. The second subfamily comprises MKP-3 (DUSP6), MKP-X (DUSP7) and 
MKP-4 (DUSP9). They are present in the cytoplasm and preferentially recognize ERK1 and ERK2 in 
vitro. HVH5 (DUSP8), MKP-5 (DUSP10) and MKP-7 (DUSP16) constitute the third subgroup as they 
preferentially recognize JNK and p38. Different DUSPs are expressed in different cell types even 
between different immune cell types. In macrophages and stimulated leucocytes high levels of MKP-
1, PAC-1 and MKP-7 are found. Studies with MKP-1 KO peritoneal macrophages show that this 
phosphatase regulates p38 and JNK with little effect on ERK. PAC-1 have preference to 
dephosphorylate ERK (Liu et al., 2007). Some DUSPs including MKP-1, MKP-2, VHR (DUSP3) and 
MKP-X are post-translationally regulated through phosphorylation which alters their stability. It has 
been shown that when MKP-1 is phosphorylated by ERK the half-life of DUSP1 is increased by 
twofold to threefold (Brondello et al., 1999). 
1.7 Role of TLR2 and NOD receptors in the recognition of Listeria monocytogenes 
1.7.1 Listeriosis 
Listeria monocytogenes is a pathogenic gram-positive bacterium responsible for foodborne illness in 
humans and animals, commonly designated listeriosis. The infection is originated via ingestion of 
contaminated food causing febrile gastroenteritis in healthy persons (Vazquez-Boland et al., 2001). 
The annual number of Listeria infection cases remains low due to the high level of resistance to the 
infection from immunocompetent individuals. However, listeriosis is one of the deadliest foodborne 
diseases and occurs mainly in high-risk groups such as elderly or immunocompromised individuals 
and pregnant women. The common symptoms are manifested as septicemia, when infection is spread 






1.7.2 Listeria dissemination, virulence factors and intracellular life cycle 
The first site of infection occurs in the intestine and L. monocytogenes stimulate DCs and resident 
macrophages, leading to an increase of Th1 type cytokines. Thus, immune responses are already 
elicited in the early stage of infection. Moreover, L. monocytogenes can cross the intestinal epithelium 
barrier through the invasion of enterocytes, specifically globet cells and M cells. The invasion of these 
cells requires the interaction of listeria protein surface InlA or InlB enterocyte-E-cadherin receptors 
(Chiba et al., 2011; Lecuit et al., 2001). After translocation L. monocytogenes spreads to the liver, 
spleen and lymph nodes.  Most of the bacteria that reach the liver is cleared from the circulatory system 
through Kupffer cells, neutrophils, NK and DCs action. However, L. monocytogenes can enter in 
hepatocytes through internalin B that binds to hepatocyte receptors and eventually replicate. In the 
spleen, bacteria inactivation by resident immune cells is less efficient than in the liver, which leads to 
extensive bacterial replication. In the case of immunosuppressed individuals, if the infection is not 
controlled at this stage, listeria disseminates to secondary organs including the central nervous system 
(CNS) and the placenta in pregnant women. The mechanism used by the bacteria to reach the CNS is 
not clear, however, some evidences propose that phagocytic cells behave as “Trojan horses”, 
transporting bacteria to the brain (Drevets, 1999). Upon crossing the blood - brain barrier, the bacteria 
invade and propagate in microglia cells. In the case of pregnant women, a similar mechanism is used 
by bacteria that is transported through maternal macrophages to trophoblast cells by cell-to-cell spread 
(Bakardjiev et al., 2005), This bacteria replication is enhanced by the immunosuppressive state 
associated to pregnancy to protect the fetus from rejection by the mother (Weinberg, 1987). Pregnancy 
listeriosis occurs mainly at the third trimester and can lead to different clinical symptoms, such as fetal 
loss, stillbirth or premature birth. Newborns can develop septicemia at the first days and later on 
meningitis, commonly termed neonatal listeriosis (Janakiraman, 2008) 
L. monocytogenes presents several virulence factors determinant for cellular invasion, survival and 
multiplication. Invasion of non-phagocytic cells is induced by interaction of listeria surface internalin 
A with the receptor E-cadherin, and internalin B to GAG receptors and c-Met receptors, respectively. 
Vip, a protein anchored in the Listeria peptidoglycan (PGN) and the endoplasmic reticulum-resident 
chaperone Gp96 interaction promote the bacterium invasion in cells (Cabanes et al., 2005). Auto 
protein is described to control the products released from the bacteria surface. GtcA glycosylates 
teichoic acids present in the bacteria cell wall contributing to Listeria invasion in epithelial cells (Faith 
et al., 2009). MprF (multiple peptide resistance factor) is implicated in the synthesis of L-PG membrane 
phospholipid and increases invasiveness of bacteria in epithelial cells and macrophages (Thedieck et 
al., 2006). Following cell invasion, L. monocytogenes escapes from the intracellular phagosomes 
through membrane lysis mediated by bacterial listeriolysin (LLO) and the phospholipases PlcA and 
PlcB. Once in the cytosol, L. monocytogenes expresses actin-assembly-inducing protein Act A that 





then regulates the passage of bacteria to neighboring cells (Pamer, 2004). In addition, L. 
monocytogenes can escape from autophagy through ActA and internalin InlK action (Cossart, 2011).  
Upon dissipation of the bacteria through the bloodstream, the resident macrophages, especially Kupffer 
cells phagocytize the bacteria. In response to the infection, macrophages secrete TNF-α and IL-12. 
These cytokines induce NK cells to produce IFN-γ, which in turns activate macrophages and 
neutrophils to produce reactive species important for macrophage-mediated killing of bacteria.  
1.7.3 Listeria recognition by PRRs and signal transduction 
Listeria expresses several TLR ligands such as PGN, flagellin and bacterial DNA, but TLR2 appears 
to be the most important TLR for surface recognition of L. monocytogenes (Torres et al., 2004). The 
early response is likely dependent of the classical MyD88-pathway (Fig. I3). Once the bacterium 
invades macrophages and escapes from the phagosomes, NOD1 and NOD2 can recognize 
peptidoglycan fragments (Leber et al., 2008), leading to the induction of pro-inflammatory cytokines. 
In addition, Listeria activates the formation of the inflammasome leading to the maturation of IL-1β 
and IL-18 (Warren et al., 2008). On the other hand, the innate response against infection by L. 
monocytogenes includes the synthesis of type I IFNs.  
Bacterial secondary messengers c-di-AMP, c-di-GMP and bacterial DNA activate the cytosolic 
receptor DDX41, DAI, cGas that recruit STING adaptor and transcription factors IRF3 and IRF7 to 
induce IFN- β (Archer et al., 2014; Burdette et al., 2011; Woodward et al., 2010). Moreover, the 
production of IFN-β in response to L. monocytogenes was found to be dependent of TLR2 in peritoneal 
macrophages (Aubry et al., 2012), whereas in bone marrow-derived macrophages is independent of 
TLRs (O'Connell et al., 2005; Stockinger et al., 2004), which indicates that specific macrophage 
populations have developed different recognition strategies for Listeria.  
1.7.4 Evasion of host IFN responses by Listeria  
Previous published data points for a detrimental role of type I IFNs to the host, during L. 
monocytogenes infection (Auerbuch et al., 2004; O'Connell et al., 2004). Type I IFNs were suggested 
to induce the downregulation of IFN-γ receptor and the induction of T cell apoptosis, which have a 
negative impact in the immune response. However, recent studies have demonstrated that type I IFNs 
can provide protection to the host during Listeria infection. Infection of mice with L. monocytogenes 
via gastrointestinal route benefited from the IFN induction in contrast of mice infected intraperitoneally 
(Kernbauer et al., 2013). Moreover, L. monocytogenes induces type I IFNs at later stages compared to 





and the timing of host type I IFNs production in response to Listeria are determinant factors for an 
efficient control of the bacterium. 
 
L. monocytogenes has the capacity to invade and replicate in macrophages, therefore circumventing 
the early innate immune responses. PGN modification is another mechanism used by the bacteria to 
evade the host immune system. PGN is a polymer that comprises alternated residues of N-
acetylglucosamine and N-acetylmuramic acid crosslinked by peptide chains. Lipoteichoic acid, tri- and 
Fig. I3 Activation of extracellular TLR and cytosolic receptors in response to Listeria monocytogenes. Bacteria 
lipoproteins are recognized at the surface by TLR2, which induces production of inflammatory cytokines via MyD88 
signaling. TLR2 is internalized and together with intracellular TLRs recognize PAMPs (lipoproteins, peptidoglycan and 
nucleic acids), which lead to TRIF-IRF3 and IRF7 signaling for type I IFN production. Cells infected by the bacteria release 
di-nucleotide and nucleic acids that activate cytosolic receptors such as DDX41, DAI, cGas and IFI16, as well as 
peptidoglycan recognized by NOD receptors. These receptors activate STING adaptor to promote IFN-β induction. 
Peptidoglycan deacetylation lows its recognition by these receptors and the bacteria evades from the immune system.  Image 





di-acylated lipoproteins are constituents of the gram-positive bacteria cell wall (Chandler and Ernst, 
2017). 
PGN modifications prevent the release of bacterial components, which includes PGN, and other cell 
wall components. However, the action of host lysozymes releases these cell wall components, which 
activate TLR2 as well as intracellular receptors such as NOD1 and NOD2. Indeed, previous studies 
demonstrated that PGN deacetylation by the deacetylase pgdA prevents its degradation by host 
lysozymes and the consequent release of PAMPs (lipoproteins, LTA). Listeria pgdA mutants were 
found to be hypersensitive to lysozymes and rapidly killed by macrophages, Moreover this strain 
induced a stronger INF-β induction and pro-inflammatory cytokines compared to the WT strain, 
mediated by TLR2 and NOD1 activation (Boneca et al., 2007). Further studies revealed that Listeria 
pgdA mutants require endosomal TLR2-TRIF signaling activation to induce IFN- β production (Aubry 
et al., 2012). Other pathogenic bacteria comprise pgdA orthologs, which suggests that PGN 
deacetylation is a general mechanism evolved by gram-positive bacteria to escape from PRR-mediated 
immune recognition (Psylinakis et al., 2005; Vollmer and Tomasz, 2000; Wang et al., 2009). 
1.8 TLR4 and TLR2 structure 
1.8.1 Structure of TLR2/1 and TLR2/6 complexes 
Bacterial lipoproteins are mostly composed of triacylated cysteines in their N-terminal, whereas 
mycoplasma lipopeptides such as MALP-2 and FSL-1 contain diacylated cysteines. Studies have 
provided structural insights into the mechanisms by which the heterodimers TLR2/1 and TLR2/6 
discriminate the structures of lipoproteins. The crystal structure of the extracellular domain of TLR2 
in association with TLR1 and a synthetic triacylated lipopeptide, Pam3CSK4, revealed that they form 
M-shaped structures (Fig. I4A) (Jin et al., 2007). In the crystal structure, the lipid chains of the ligand 
bridge the TLRs; two of the three lipid chains are inserted into an internal hydrophobic pocket in TLR2, 
and the remaining amide-bound lipid chain is inserted into the narrower channel of TLR1. The crystal 
structure of mTLR2/TLR6 -Pam2CSK4 complex was solved (Fig. I4B) (Kang et al., 2009). Diacylated 
lipopeptides lack the amide-bound lipid chain, which is essential for TLR2/TLR1 response. Thus, it 
has higher affinity for TLR6 since its pocket contains two bulky phenylalanines at the entrance and a 
high hydrophobic area. Therefore, the amide-bound lipid chain of triacylated lipopeptides is not able 
to interact with TLR6. Modeling of TLR10/TLR2 lipopeptide complex reveals structural similarity to 
the solved crystal structure TLR2/1/lipopeptide complex. Similar to TLR1, the model predicts a 
hydrophobic channel on the convex surface of TLR10 that accommodates the amide-linked lipid chain 






1.8.2 TLR4/MD-2/LPS complex crystal structure 
The crystal structure of TLR4/MD-2 receptor with E. coli LPS indicates the formation of an M-shaped 
structure made up of two molecules of TLR4 and two molecules of MD-2 (Park et al., 2009). E. coli 
LPS lipid A contains a β (1→ 6) linked phosphorylated glucosamine disaccharide backbone and C12 
and C14 acyl chains there are directly linked to the disaccharide, and the secondary acyl chains are 
esterified with the hydroxyl groups of primary acyl chains (Fig. I5A). E. coli lipid A is accommodated 
in the MD-2 pocket such that five of six acyl chains are buried inside the pocket and the sixth chain is 
exposed to the surface of MD-2 (Fig. I5B). MD-2 pocket size is unchanged and the additional space 
for lipid binding is generated by glucosamine backbone displacement upwards. The two phosphates of 
this backbone are important for dimerization, through interaction with positively charged lysine and 
arginine residues in TLR4, TLR4∗, and at the entrance of MD-2 pocket (e.g. Lys91, Ser118, Ser120 
and Lys122 for MD-2 and Arg264, Lys341, Tyr296 for TLR4). The exposed FA chain contributes to 
complete the dimerization interface, interacting with TLR4* (Gln 436). The sugars present in the inner 
core of E. coli LPS consist of three units of 3-deoxy-d-manno-2-octulosonic acid (KDO I, II, III) and 
three units of heptosyl-2-keto-3-deoxy-octulosonate (Hep I, II, III) which stablish hydrogen bonds with 
MD-2 and TLR4 (e.g., Tyr296, Asp294, Lys341 Lys122) but not with TLR4*. Thus, it is speculated 
Fig. I4 Overall structure in side and top view of A) human TLR1/TLR2/Pam3CSK4 complex and B) mouse TLR6/TLR2/ 
Pam2CSK4 complex. Ligands are displayed in red. Each TLR structure represents the three domains: N-terminal, central 






that the core has a minor role in the immunological activity of LPS. The number of acyl chains in the 
lipid A can affect TLR4 dimerization. In contrast to the hexaacylated E. coli lipid A, the tetraacylated 
precursor molecule, lipid IVA or the synthetic molecule Eritoran display antagonistic activity for TLR4 
signaling. The crystal structures of lipid IVA or Eritoran in complex with TLR4/MD-2 were solved 
(Ohto et al., 2007; Ohto et al., 2012). The four-acyl lipid A is completely buried in the MD-2 pocket 
to fill the empty space and cannot promote the hydrophobic dimerization at the surface. This 
downwards shift of the lipid A greatly affects the interaction of the two phosphate groups with the 
positively charge groups in the MD-2 and TLR4 surface.  Bacteria such as Yersinia pestis expresses a 
hexa-acyl lipid A at 28ºC, but this structure is mainly tetra-acylated at 37ºC (host 
temperature)(Kawahara et al., 2002). In addition, F. tularensis regulates lipid A acyl chain length 
according to temperature where at 37ªC, express a lipid A with longer acyl chains, thus attenuating 
TLR4 recognition (Okan and Kasper, 2013). 
 
 
Besides the number of acyl chains, the number of phosphate groups is another bacterial strategy to low 
recognition by the immune system. Francisella tularensis lack one phosphate group in one of the 
A B 
Fig. I5 A) Full E. coli LPS structure composed of lipid A acylated chains linked to a 1,4′-diphosphorylated β (1→6) 
glucosamine (GlcN) disaccharide (in red). To the lipid A is attached a core oligosaccharide and a distal O-antigen. The inner 
core is composed of KDOs and heptoses with phosphate residues. Hydrogen bonds with MD-2 residues are shown in pink 
and with TLR4 residues in blue.  B) Full structure in side and top view of the human dimer TLR4/MD-2/E.coli LPS. The 






backbone sugars and is considered to contribute for its weak TLR4 agonistic activity (Molinaro et al., 
2015). Porphyromonas gingivalis can harbor different lipid A species, from non-phosphorylated to 
mono or di-phosphorylated and penta- and tetra-acylated structures, depending on the temperature. At 
37 º C, tetra-acylated non-phosphorylated lipid A is predominant.  Thus, the number of acyl chains and 
phosphates groups in the lipid A greatly influence TLR4/MD-2 dimerization and the consequent host 
immune response.  
1.9 Atypical LPS recognition by TLR2 receptor 
Several studies have highlighted that the biological activity of some LPSs is not restricted to TLR4. 
Indeed Leptospira interrogans, Legionella pneumophila and Rhizobium species sin-1 LPSs induce 
TLR2-mediated inflammatory responses in immune cells (Burns et al., 2010; Girard et al., 2003; 
Hirschfeld et al., 2001; Werts et al., 2001). These LPSs, typically termed non-classical LPSs show a 
different structure and composition compared with the classical enterobacterial-type LPSs. These LPSs 
contain a diaminoglucose disaccharide backbone and at least one very long fatty acid chain (VLCFAs) 
in the lipid A domain. α-Proteobacteria like Brucella and Ochrobactrum express this type of LPS (Fig. 
I6A). Brucella is an animal pathogen and evolved a stealthy strategy to avoid innate immunity 
recognition. In contrast, Ochrobactrum is a soil-living organism but is another opportunistic bacterium 
and phylogenetically is the closest member to Brucella. Both bacteria express LPSs with a similar lipid 
A but distinct core saccharide and O-antigen. The lipid A comprises six acyl chains in amide linkages 
and include a VLCFA with 28 carbons (Lapaque et al., 2006). The N-linked fatty acyl chains role in 
the low endotoxicity of these LPSs is not clear. It is speculated that provides more stability to the outer 
membrane at elevated temperatures and extreme pH due to the greater bond strength  (Trent et al., 
2006). Ochrobactrum LPS contains a core with two KDO molecules, a side branch composed of Manp 
and GlcpN residues. The KDO II connects the lipid A to the O-antigen followed by a Galp and Glcp 
sugars (Fig. 6A). On the other hand, Brucella LPS harbors a core saccharide with a larger side branch 
comprising four GlcpN residues and the other branch contains a Glcp linked to KDO II (Barquero-
Calvo et al., 2009; Fontana et al., 2016). Ochrobactrum intermedium LPS showed immunostimulant 
properties for prevention and treatment of sepsis, as well as adjuvant for vaccines in immunosuppressed 
animals (Ovejero Guisasola, 2012). This LPS contains a hexaacyl-lipid A made of a diaminoglucose 







Similar to O. anthropi, the O. intermedium core comprises a Manp and GlcpN but both contain a 
phosphate group. However, the O-antigen core branch contains sugars such as acetylated GlcpN and 
rhamnose. This core composition departs from the typical heptose sugar repetitions observed in E. coli 
core (Brooke and Valvano, 1996; Velasco et al., 2000). The presence of these VLCFAs and a diverse 
sugar core reduce the reactivity of these LPSs. This was observed previously, where cell stimulation 
with high concentrations of Brucella LPS, induced a weak final response (Barquero-Calvo et al., 2009; 
Duenas et al., 2004). 
It was previously demonstrated cytoplasmic TLR2-TLR4 binding through enzyme complementation 
assays (Lee et al., 2004). Moreover, other study have highlighted that TLR2 is required along with 
TLR4 for the response to gram-negative bacterial LPS, and involves a physical interaction between 
TLR2 and TLR4 in cells from renal tubules (Good et al., 2012). This supports the concept of TLR4 
and TLR2 heterodimers formation, depending of the ligand. 
B A 
Fig. I6 Structure model of A) Ochrobactrum and Brucella lipid A and core saccharide portion (adapted from (Barquero-
Calvo et al., 2009). B) Ochrobactrum intermedium LPS. The lipid A is composed of a linked 2,3-diamino-2,3-dideoxyglucose 
backbone with two phosphate groups and four fatty acid chains attached, carrying two radical groups (C19 and C28 chains). 



















 AIM OF STUDY 
2 AIM OF STUDY 
The overall aim of this study was to increase our understanding of TLR2 signaling, receptor 
dimerization and inflammatory response pattern compared to TLR4 signaling. Understanding TLR2 
biology and function is important, as these receptors can be targets for immune modulating compounds 
against certain bacterial infections.  
 
 In this study, the objectives were as follows: 
1. Study the differential signaling in response to TLR2 and TLR4 ligands and the consequence 
in the final inflammatory response; 
2. Determine the role of TRIF signaling in TLR2-mediated inflammatory response and the effect 
of TLR2 ligands in the prevention of the gram-positive bacteria Listeria monocytogenes; 
3. Address the ability of the atypical Ochrobactrum intermedium LPS to induce the 




















 MATERIALS AND METHODS 
3 MATERIALS AND METHODS 
 3.1 Materials 
 3.1.1 Reagents 
Name Reference Commercial House 
E. coli LPS L8274 Sigma 
Pam3CSK4 tlrl-pms InvivoGen 
FSL-1 tlrl-fsl InvivoGen 
Ochrobactrum intermedium LPS patent WO2010/139352  
PD98059 BML-EI360-0005 Enzo Life Sciences 
PKCζ inhibitor BML-P219-0500 Enzo Life Sciences 
U0126 19-147 Merck Milipore 
SB203580 152121-47-6 Cayman 
SB239063 S0569 Merck 
FR180204 SML0320 Merck 
5Z-7-oxozeaenol 66018-38-0 Calbiochem 
Manumycin A 52665-74-4 Calbiochem 
Dynasore D7693 Merck 
Chlorpromazine C8138 Merck 
Chloroquine C6628 Merck 
Recombinant mouse IFN-β 8234-MB-010 R&D systems 
Anti-mouse IFN-β 32400-1 PBL assay Science 
Recombinant murine GM-CSF 315-03 Peprotech 






 MATERIALS AND METHODS 
3.1.2 Antibodies 
Name Reference Commercial house Application 
IκBα 9242 Cell Signaling WB 
p38 9212 Cell Signaling WB 
pp38 (Thr180/Tyr182) 9211 Cell Signaling WB 
ERK1/2 9102 Cell Signaling WB 
pERK1/2 (Thr202/Tyr204) 9101 Cell Signaling WB 
MKP1 V-15 sc-1199 Santa Cruz Biotechnology WB 
IRF3 4302 Cell Signaling WB 
pIRF3 (Ser396) 4947 Cell Signaling WB 
IRF7 ab109225 Abcam WB 
pIRF7 (Ser437/438) 24129 Cell signaling WB 
β-actin sc-47778 Santa Cruz Biotechnology WB 
TLR2 CD282 T2.5 121802 Biolegend FACS/IF 
TLR4  Ab13556 Abcam FACS 
F4/80 12-4801-80 eBioscience FACS 
CD16/CD32 Fc block 553142 BD Biosciences FACS 
Anti-rabbit Alexa Fluor 647 A-31573 ThermoFisher FACS 
Anti-mouse Alexa Fluor 647 A-31571 ThermoFisher FACS 
Anti-mouse Alexa Fluor 555 A-31570 ThermoFisher IF 
DAPI 268298 Merck IF 
Prolong Glass Anti-fade  P-36982 ThermoFisher IF 
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3.1.4 Cell lines 
The murine macrophage cell line RAW264.7 was cultured in RPMI 1640 medium (Gibco) (2mM L-
glutamine, antibiotics), supplemented with 5% FBS. Cells were cultured in 12-well plates for protein 
or in 6-well plates for RNA and serum deprived for 18 hours prior stimulation. HEK293T were cultured 
in DMEM (Gibco) (2mM glutamine, 2mM AANE, antibiotics) with 5% FBS. 








































 MATERIALS AND METHODS 
3.1.5 Mice  
C57BL/6 female mice, TLR2, TLR4 and TLR2/4 KO mice were obtained from S. Akira. All mice 
were bred and maintained in the animal facilities of the Centro de Biologia Molecular Severo Ochoa 
in Universidad Autonoma de Madrid. All animal procedures were performed according to the 
European and Spanish regulations. 
3.2 Methods 
3.2.1 Ligands and inhibitors preparation 
Pure TLR4 ligand LPS, synthetic TLR2/1 ligand Pam3CSK4 and TLR2/6 ligand FSL-1 were 
resuspended in sterile PBS 1x and added to the culture medium to the indicated concentrations.  
Inhibitors were dissolved in DMSO and added to the culture medium at the indicated concentrations 
(DMSO final concentration at 0,1%).  
3.2.2 In vivo model of neonatal listeriosis 
Pregnant C57BL/6 female mice were infected with bacterial suspensions of Listeria in PBS (10000 
CFUs/mL) by intravenously injection at 11 days of gestation (infected mother´s group). FSL-1 was 
administrated (10ug/Kg) at the same time as the infection in pregnant mice (infected and treated 
mothers’ group). A control group consisted in mice injected only with PBS (non-infected group). 4 
days after birth, neonates from infected and infected and treated mothers were sacrificed to obtain the 
brain for CFU measurement and for isolation of primary microglia cells for cytokine quantification. 
The neonate´s liver and spleen were also harvested for CFU measurement. Mothers from control, 
infected and infected and treated group were sacrificed to isolate the liver and spleen for bacteria load 
quantification and blood sera was extracted for cytokine measurement. Organs were homogenized by 
mechanical disruption in a 70µM strainer. Serial dilutions of the homogenates were plated on BHI agar 
plates and colonies were counted after overnight incubation at 37ºC.  
3.2.3 Microglia isolation by MACS 
Microglia cells were obtained from neonate brains with 4-days. The brains were homogenized and the 
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4ºC. Microglia cells are finally isolated by magnetic separation and cultured for further supernatant 
collection. 
3.2.4 Isolation of primary macrophages 
3.2.4.1 Isolation of mouse peritoneal macrophages 
Peritoneal macrophages (PM) were isolated from 6-8-week-old pathogen-free mice. Briefly, mice were 
injected intraperitoneally 1 mL of 4% thioglycollate. Four days later, cells were harvested by peritoneal 
lavage with cold PBS. Cells were recovered by centrifugation and cultured in RPMI 1640 (2mM L-
glutamine, antibiotics) with 5% FBS. Cells were seeded into 12 or 6-well-pates at a density of 1 x 106 
cells/well. Cells were allowed to adhere for 2 h and then the medium was changed to remove non-
adherent cells. After 24 h, medium was replaced with new complete medium before the respective 
treatment. 
3.2.4.2 Isolation of mouse bone marrow-derived macrophages and dendritic cells 
Bone-marrow cells were isolated from femurs of female 6-8-week-old mice and collected in ice cold 
PBS. Bones were flushed with RPMI 1640 (2mM L-glutamine, antibiotics) supplemented with 5% 
FBS. These cells were cultured in 6-well plates with medium + 20% L929 supernatants (a source of 
M-CSF) to differentiate in macrophages or with GM-CSF to differentiate in dendritic cells until day 7, 
where a homogeneous population of adherent macrophages was obtained. Cells were then deprived of 
L929 supernatants or GM-CSF for 2 h before carrying out the stimulation assays. MKP-1 and TRIF 
KO macrophages were obtained from a collaboration with Rosario Perona(xx) and Gloria Gonzalez-
Aseguinolaza respectively (Center for Applied Research, Pamplona, Spain). 
3.2.5 Mouse dendritic cell’s infection assay 
DC’s were cultured in RPMI 1640 with 5% FBS. After 7 days of differentiation DC’ s were infected 
with Listeria at a MOI 1:10 (cells/bacteria), centrifuged 5min at 700g for bacteria infection 
synchronization, followed by incubation at 37ºC for 15 min. Following phagocytosis, cells were 
washed and incubated in 5% FBS/RPMI medium with gentamicin (30ug/mL) for 45 min, to kill non-
internalized extracellular bacteria. After infection, cells were treated with the different ligands and 
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were lysed in 0.2% Triton X-100 at 24 hours, and the number of viable bacteria released from the cells 
was assessed after serial dilutions of the lysates on BHI agar plates. 
3.2.6 Real-time quantitative PCR 
Total cellular RNA was isolated using NZyol Reagent (NZYTech). cDNA was prepared by reverse 
transcription (GoTaq 2-Step RT-qPCR System, Promega) and amplified by PCR using SYBR® Green 
PCR Master Mix and ABI Prism 7900HT sequence detection system (Applied Biosystems) All samples 
were run in triplicate. All quantifications were normalized to the housekeeping genes, GADPH and 
RPL13A to account for the variability in the initial concentration of RNA and in the conversion 
efficiency of the reverse transcription reaction (ΔCT) and to values from control samples. The relative 
quantity (RQ) was calculated as RQ = 2 -ΔΔCT 
3.2.7 Enzyme-Linked Imunosorbent Assay (ELISA) 
Cytokine concentration was determined for IL-10, TNF-α, IL-6 and IL2-p40 and IFN-β using ELISA 
kit purchased from R&D systems or CBA kit. Briefly, experimental supernatants were collected and 
centrifuged at 3,000 g for 5 min. Supernatants were analyzed in duplicate per manufacturers protocol. 
3.2.8 Protein extraction and Western blot 
Cells were washed with ice-cold PBS and solubilized in ice-cold lysis buffer (50mM Tris pH 7,5, 150 
mM NaCl, 1% Triton X-100, 1mM EDTA, 10% Glycerol + Phosphatase and Protease inhibitors from 
Roche). Protein concentration was determined by the bicinchoninic acid (BCA) method (Pierce). 
Western blot analyses were performed as follows: equal protein amount (20 µg) from each cell lysate 
were loaded and separated on SDS 10% polyacrylamide gel and transferred to a nitrocellulose 
membrane (Bio-Rad). Membranes were blocked with 3% BSA for 1 h and incubated with the primary 
antibodies overnight. The membranes were then incubated with HPR-conjugated secondary antibodies 
for 1 h. The membranes where developed using ECL substrate (BioRad). 
3.2.9 Fluorescence-activated cell sorting (FACS) 
3x105 cells were washed with PBS and blocked with 1% BSA with CD16/CD32 Fc block antibody for 
20 min at 4ºC. Cells were consequently incubated with anti-TLR2 CD282 T2.5 antibody or TLR4 
antibody for 20 min (1:100). Cells were incubated with an anti-mouse or anti-rabbit secondary antibody 
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ressuspended in PBS with 1% BSA. Cells were analysed in FACS Canto II, collecting 30 000 events 
per sample and the results were analysed in FlowJo 7.0 software.  
3.2.10 Immunofluorescence 
Raw 264.7 cells were plated in coverslips, into 24-well plate at seeded at density of 1 x 105 cells/well 
overnight, in RPMI 1640 (2mM L-glutamine, antibiotics) with 5% FBS. The next day, cells were 
stimulated with LPS, Pam3CK4 or FSL-1 for 3 mqin. Cells were washed 3 times with PBS 1x and 
fixed with PFA 4% for 10 min. Cells were incubated with 50 mM NH4Cl, pH 8 for 10 min to eliminate 
the autofluorescence. The cells were then blocked 1% BSA for 1 hour and incubated with the primary 
antibodies anti-TLR2 CD282 T2.5 (1:200). Cells were further incubated with Anti-mouse Alexa Fluor 
555 (1:1000) for 1 hour. Cells were consequently stained with DAPI (1: 7500). Coverslips were 
mounted in slides with Prolong Glass Anti-fade. The samples were observed in Zeiss LSM 710 
Confocal Microscope. 
3.2.11 Molecular docking 
3.2.11.1 Ligands construction and preparation 
The full structure of E. coli LPS was extracted from the (TLR4/MD-2/E. coli)2 complex retrieved from 
the Protein Data Bank (PDB) under the accession code 3FXI. The 3D structure of Ochrobactrum 
intermedium LPS was constructed using PyMOL molecular graphics (DeLano, 2002). O. intermedium 
LPS structure was then divided into fragments: IV core (fragment containing the saccharide core of 
the LPS), IV28 (fragment with the two fatty acid chains containing 12 and 16 carbons and the third 28 
carbon acyl chain attached to C16), IV19 (fragment containing the two lipid chains with 14 and 18 
carbons and the third 19 carbon lipid chain attached to C18), IV lipid A (all the lipid A part containing 
the two phosphorylated glucosamines and the six fatty acid chains).  Cuts were introduced as hydrolysis 
of ether bonds, thus a hydrogen atom was added to the oxygen atom of the fragment. The full ligands 
and the fragments were minimized with Schrodinger Maestro software (Schrödinger, 2018) using the 
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3.2.11.2 Construction of a TLR4/TLR2 dimer and TLR2/MD-2 monomer models 
The crystal structure of hTLR2/6 dimer (2Z7X) and hTLR4 (3FXI) were retrieved from the PDB. 
PyMOL software was used to superimpose TLR2 to one of the TLR4 from the dimer. The final 
structure comprises TLR4/MD-2 dimer as found in 3FXI and TLR2 that was superimposed, the 
remaining atoms were deleted. The TLR2/MD-2 model was obtained by superimposition of hTLR2/6 
dimer and hTLR4 dimer, deleting atoms from TLR4 and one of the MD-2. The structures went through 
a minimization with Amber14 (Case, 2014) under the ff14SB (Maier et al., 2015) to minimize the 
newly constructed TLR4/TLR2 interface. 
3.2.11.3 Ligand-protein docking for full LPS and fragments 
The Gasteiger charges were computed for ligands and receptors using the AutodockTools 1.5.6 
software (Sanner, 1999) and non-polar hydrogens of the receptors were merged. The structure of the 
receptors was kept rigid whereas all ligands were set to be partially flexible considering the rotable and 
non-rotable bonds determined by the program. Autodock Vina (Oleg Trott, 2010) was used to perform 
the docking calculations. Each ligand was docked into different regions of hTLR2 monomer and 
hTLR2/TLR4/MD2 heterodimer complex. For all the docking boxes, the point spacing was set as 1 Å. 
For hTLR2, a docking was performed with the box covering the TLR2 pocket (Docking A) with a 
center placed between residues Phe284, Leu282 and Asn274, and a box size of 40, 36, 30 (X, Y, Z).  
For hTLR2/TLR4/MD-2 heterodimer, a docking was performed in the region behind hTLR2 
containing the N-terminal and central subdomains (Docking B), were the box was centered between 
residues Arg321, His318 and Asn290 with a size of 37, 50, 50 (X, Y, Z). Other box was set to cover 
the interface of TLR2 and TLR4 receptor (Docking C) with center coordinates of Lys324 (TLR4), 
Tyr376 (TLR2) and Asn379 (TLR2) (X, Y, Z) and size 37, 50, 50 (X, Y, Z). The docking was also 
performed inside the MD-2 pocket (Docking D) setting a box where the center of coordinates were 
Phe119 (TLR4), Ile52 (MD-2) and Ser57 (MD-2) (X, Y, Z) and size 36, 38, 50 (X, Y, Z). A docking 
covering the entire hTLR2/TLR4/MD-2 heterodimer was also performed (Docking E), setting a box 
with the center coordinates Glu321 (TLR4), Glu375 (TLR2) and Lys378 (TLR2) and the size was 45, 
84, 62 (X, Y, Z). The determination of the best result from each docking was based on the predicted 
binding energy and the mode of interaction of the ligands. Docking poses were analyzed and structural 





 MATERIALS AND METHODS 
3.2.12 Cell transient transfection and FRET imaging 
Analysis of association of the TLR4 and TLR2 monomers by LPS O. intermedium stimulation was 
performed by FRET (Förster resonance energy transfer), using CFP-tagged TLR2 and YFP-tagged 
TLR4 monomers. HEK293T cells were seeded in 6-well plates (3x105 cells/well) and incubated 
overnight in DMEM with FBS 5% without antibiotics. In the next day, cells were transiently 
transfected using Metafectene Pro (Biontex). Cells were co-transfected with 0.5 µg of plasmid mixture 
of pcDNA3-TLR4-YFP, pcDNA3-TLR2-CFP or transfected with each plasmid (molar ratio 1:1). Cells 
were also transfected with the plasmid pCMV-ECFP-EYFP that expresses the tandem CFP:YFP 
construct, which served as a positive control for FRET. Briefly, DNA and metafectene were diluted in 
Optimem for 5 min and then the DNA was mixed to the Metafectene during 15 min, to a ratio of 
DNA:Metafectene 1:3. This mix was added to the cell medium and incubated for 6 hours. Then, cells 
were seeded in eight-well glass bottom chambers (4x104 cells/well) and incubated overnight in phenol 
red-free DMEM with FBS 5% and HEPES 25mM. Next day, cells were stimulated with LPS O. 
intermedium at a final concentration of 1 µg/mL.  
FRET between TLR2 and TLR4 proteins was calculated by measuring sensitized emission 
fluorescence of CFP-YFP pair using NIS Elements 4.40 software on the Nikon Eclipse Ti-E confocal 
microscope. Images of live cells were captured at 60x magnification, under oil immersion. In sensitized 
emission FRET, the acceptor (YFP) emission is measured as a result of donor (CFP) excitation. Images 
from three channels are acquired: CFP channel (a CFP excitation and emission filter), a YFP channel 
(a YFP excitation and emission filter) and a FRET channel (containing a CFP excitation filter and a 
YFP emission filter).  CFP and YFP channel are used to correct the FRET image, because the donor 
emission can bleed-through into the FRET channel and because CFP excitation wavelength can excite 
the acceptor YFP, giving false positive FRET signals.  Thus, cells expressing only TLR2-CFP or only 
TLR4-YFP are used as controls. First, images of cells expressing TLR4-YFP were taken, exciting YFP 
with a 513-laser line and the 458 laser, each time collecting images in the FRET channel (Em 527 nm). 
Then, images of cells expressing TLR2-CFP were obtained, exciting CFP at 458 nm and acquiring 
images in both the CFP (Em 480nm) and FRET channel. These images are used to calculate the 
correction factors A (percentage of YFP in the FRET channel) and B (percentage of CFP in the FRET 
channel). ROIs were drawn in images of cells expressing only TLR4-YFP as well as in regions without 
cells to correct for background. The average of intensity values from all acquired YFP images give the 
correction factor A. The same procedure was performed for images of cells expressing only TLR2-
CFP to calculate the correction factor B. Applying the following equation: 
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A corrected FRET image (FRETCorr) is obtained from the FRETRaw image of cells co-expressing TLR4-
YFP and TLR2-CFP as well as for the CFP:YFP construct. The FRET efficiency is shown as a color-
coded scale of values between 0 and 100%. Quantification of the number of FRET positive structures 
in the cells, as well, as the mean fluorescence intensity of each structure was determined in ImageJ, 
applying a threshold in grayscale images, to eliminate the background and only select positive FRET 
signal structures. 
3.2.13 Statistics 
Analysis was performed with GraphPad Prism 5 software. Statistical analysis between two groups was 
performed using two-tailed unpaired Student’s t-test. Two or more groups were compared with one-






















4.1 CHAPTER 1: TLR4 and TLR2 differential kinetics on early signaling activation: the 
outcome in inflammation 
4.1.1 TLR4 and TLR2 ligands induce a distinct cytokine pattern 
TLR’s activation by various microbial-derived components induce distinct inflammatory responses in 
macrophages that may fine-tune the acquired immune response. To determine whether TLR2 and 
TLR4 differ in their ability to activate macrophage responses, Raw264.7 cells were stimulated with 
specific ligands for TLR4 (LPS), TLR2/1 (Pam3CSK4) and TLR2/6 (FSL-1). The LPS stimulus 
induced higher trnascription levels of IL-6, IL-12p40, TNF-α and iNOS but lower induction of IL-10 
cytokine and ARG1 than TLR2 ligands (Fig. 1).  
 
 
On the other hand, TLR2 ligands induced higher levels of IL-10 and ARG1, but lower activation of 
pro-inflammatory cytokines than LPS. To ensure that the differential cytokine induction observed in 
Raw264.7 cells was not a cell-line occurrence, the same experiment was performed using wild-type 
Fig. 1 TLR4 and TLR2 ligands induce a distinct cytokine expression pattern in Raw264.7 cell line. 
Raw264.7 cells were stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) for 24 h. Cytokines 
mRNA expression was assayed by quantitative RT-PCR, normalized to GAPDH, and presented relative to unstimulated cells 





peritoneal macrophages (PM). When these cells were treated with LPS, Pam3CSK4 or FSL-1, a similar 
pattern on cytokine’s induction was observed by TLR4 and TLR2 activation (Fig. 2). 
 
 
This indicates that TLR2 ligands induce a more anti-inflammatory response compared to TLR4 ligands 
observed by the higher IL-10/IL-12p40 ratios. Furthermore, there was also some differences between 
distinct TLR2 ligands, since FSL-1 induced a higher IL-10/IL-12p40 ratio compared with Pam3CSK4, 
which suggests that distinct TLR2 ligands can elicit slightly different inflammatory responses. 
Moreover, these results demonstrate that both immune cell types (cell line vs primary cell) have a 
similar cytokine induction profile via TLR4 and TLR2 receptors. 
 
4.1.2 TLR4 and TLR2 ligands exhibit different kinetics on NF-B and MAPK pathways 
activation 
Since TLR4 and TLR2 receptor's activation induce a distinct cytokine pattern, the next step was to 
examine whether TLR4 and TLR2 ligands could differentially activate the cell signaling pathways. 
Raw 264.7 cells were serum starved and then stimulated for 3, 10, 30 and 60 minutes with LPS, 
Pam3CSK4 or FSL-1. We detected NF-B activation by IBα degradation in response to LPS around 
30 and 60 min. Similar kinetics was observed for activation of MAPKs ERK and p38, where detectable 
Fig. 2 TLR4 and TLR2 ligands induce a distinct cytokine expression pattern in peritoneal macrophages. 
Peritoneal macrophages were stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) for 24 h. 
Cytokines mRNA expression was assayed by quantitative RT-PCR, normalized to GAPDH, and presented relative to 






phosphorylation appears at 30 and 60 min (Fig. 3). Interestingly, TLR2 ligands activate these signaling 
pathways faster; by 3 min after stimulation, IBα degradation and the phospho-MAPKinase pathway 




Despite the striking difference in the activation kinetics between TLR4 and TLR2 ligands, no apparent 
changes in the signal strength of activation were observed. In peritoneal macrophages, a similar kinetic 
signature was observed (Fig. 5). Peritoneal macrophages from TLR2 KO and TLR4 KO mice were 
also used to confirm the ligands stimulation-specificity. Upon stimulation of TLR2 KO macrophages, 
TLR2 ligands were unable to activate MAPK or NF-B pathways, indicating the specificity of these 
ligands for TLR2 receptor. As expected, LPS was able to activate these cells but not TLR4 KO 
macrophages. 
Fig. 4. Raw264.7 cells were stimulated with incremental doses of Pam3CSK4 and FSL-1indicated in the image at 3, 10, 30 
and 60 min and stained with the indicated antibodies. The image is representative of one experiment. 
Fig. 3 TLR4 and TLR2 ligands exhibit different kinetics on NF-κB and MAPK pathways activation.   
Raw 264.7 cells were treated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min 
and stained with the antibodies indicated on the right side of the panels. The graphics below show the quantification of band 





4.1.2.1 MEK- independent mechanism contributes for ERK1/2 activation by TLR2 
ligands in the Raw264.7 cell line 
To study the differential kinetic signaling between TLR4 and TLR2 ligands, special focus was given 
to investigate whether different upstream ERK and p38 activators could be induced via TLR4 or TLR2 
activation. To this end, Raw264.7 cells were pretreated with TAK1 inhibitor (5Z-7-oxzeaenol) and 
MEK 1/2 inhibitors (PD98059 and U0126) once these mediators are described to be implicated in ERK 
activation. In the presence of TAK1 inhibitor, ERK and p38 phosphorylation were reduced upon 
stimulation with TLR4 and TLR2 ligands (Fig. 6A) suggesting that TAK1 is an upstream activator for 
these MAPKs. The same pattern was observed for the stimulation of peritoneal macrophages (Fig. 6B). 
The role of the MEK1/2 kinase in ERK activation by TLR2 activation was addressed. Cells were 
pretreated with MEK1/2 inhibitor PD98059 that has been described has an inhibitor of MEK1 
activation and to a lesser extent MEK2, with IC50 values of 4 µM and 50 µM respectively (Alessi et 
al., 1995). A 50 µM concentration of PD98059 was sufficient to fully block ERK phosphorylation 
upon stimulation of LPS (Fig. 7). However, this inhibitor only inhibited a small fraction of ERK 
phosphorylation in response to Pam3CSK4 and FSL-1. To ascertain that this phenomenon was not 
dueto a limited inhibition of MEK2 activity, a higher dose of PD98059 was tested (100 µM), but ERK 
phosphorylation in response to Pam3CSK4 and FSL-1 was maintained (Fig. 8).  
Fig. 5 TLR4 and TLR2 ligands responses are specific of TLR4 and TLR2 receptor respectively.  
WT peritoneal macrophages, TLR2 KO and TLR4 KO peritoneal macrophages were left untreated (c) or treated with LPS 










Fig. 6 TAK1 is an upstream activator of ERK and p38 in the Raw264.7 cell line and peritoneal macrophages. 
A) Raw264.7 cells and B) peritoneal macrophages were pretreated with 1 µM 5Z-7-oxzeaenol (“TAK1”) for 30 min. Cells 
were left unstimulated (c) or stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 
and 60 min. A representative western blot is shown of three independent experiments. 
Fig. 7 PD98059 weakly inhibits ERK activation in response to TLR2 ligands in the Raw 264.7 cells line. 
Raw 264.7 cells were pretreated with 50 µM PD98059 (“PD”) for 30 min. Cells were left unstimulated (c) or stimulated with 
LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min. A representative western blot 
experiment is shown of three experiments. Graphics show quantification of band intensities of the upper western blot.  The 
values of p-ERK 1/2 bands were normalized to the total ERK 1/2 protein. Data are representative of three independent 






U0126 was tested in Raw264.7 cells since this inhibitor has 100-fold higher affinity for MEK1/2 than 
PD98059, with similar IC50 values for MEK1 and MEK2 (0,06 µM and 0,07 µM respectively) (Favata 
et al., 1998). In the presence of U0126 inhibitor, ERK activation by LPS was fully impaired. However, 
in response to Pam3CSK4, ERK phosphorylation peak appeared at 60 min, and was inhibited to 67% 
in the presence of U0126 (Fig. 9). Regarding FSL-1 stimulation, ERK activation was higher at 10 and 
30 min and when treated with U0216, ERK phosphorylation was still observed (approx. 25%). 
 
 
These results show that PD98059 and at a lesser extent U0126, weakly inhibits ERK activation in 
response to TLR2 ligands. This phenomenon prompted us to examine the effect of these inhibitors on 
ERK activation in primary cell macrophages. Peritoneal macrophages were pretreated with each MEK 
Fig. 8 Raw 264.7 cells were pretreated with two doses of PD98059 (“PD”) as displayed in the images for 30 min. Cells were 
left unstimulated (c) or stimulated with Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min. A 
representative experiment is shown from one experiment. 
Fig. 9 A MEK-independent mechanism contributes for TLR2-mediated ERK activation in the Raw264.7 cell line.  
Raw 264.7 cells were pretreated with 1 µM U0126 for 30 min. Cells were left unstimulated (c) or stimulated with LPS (100 
ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min. A representative western blot experiment is 
shown of three experiments. Graphics show quantification of band intensities of the upper western blot.  The values of p-
ERK 1/2 bands were normalized to the total ERK 1/2 protein. Data are representative of three independent experiments (mean 





inhibitor and stimulated with the three different ligands. ERK phosphorylation in response to the three 
ligands was impaired in the presence of PD98059 inhibitor as well as in the presence of U0126 (Fig. 
10A and 10B). 
 
Fig. 10 PD98059 and U0126 inhibitors downregulate ERK activation in peritoneal macrophages, regardless of the 
stimuli.  
Peritoneal macrophages were pretreated with A) with 50 µM PD98059; B) with 1 µM U0126 for 30 min. Cells were left 
unstimulated (c) or stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 
min. A representative Western blot is shown of two experiments. Graphics show quantification of band intensities of the 
upper western blot. All densitometry values of the p-ERK 1/2 band were normalized to the total ERK 1/2 protein. Data are 







The same effect was observed for LPS and FSL-1 stimulated bone marrow-derived macrophages 
(BMDM) pretreated with PD98059 (Fig. 11). Therefore, a TAK1-MEK- independent mechanism 
contributes for ERK1/2 activation by TLR2 ligands only in the Raw264.7 cell line. 
 
4.1.2.2 ERK activation by TLR2 ligands is Ras-dependent and PKCζ–partially 
dependent in Raw264.7 cells 
It is described that Ras-MEK as well as PKCζ-MEK pathways are activated by LPS and induce ERK 
phosphorylation (Monick et al., 2000; Pathak et al., 2004). Moreover, PI3K-mTOR, TPL2 are also 
described to contribute for ERK activation in response to LPS. Therefore, PI3K, TPL2, Ras and PKCζ 
inhibitors were tested in order to access their influence in the MEK-independent pathway activated by 
TLR2 ligands in Raw264.7 cells. Inhibition of PI3K (wortmannin) and TPL2 did not affect ERK 
activation upon TLR2 ligands stimulation (data not shown). On the other hand, cells stimulated with 
LPS show ERK activation at 30 and 60 min, which is impaired in the presence of Ras inhibitor (Fig. 
12A). The same effect is observed for Pam3CSK4 and FSL-1 stimulation as ERK phosphorylation is 
present mainly at 3, 10 and 30 min and disappears in the presence of the inhibitor. However, the effect 
of PKCζ inhibition in ERK phosphorylation differs. PKCζ inhibition impairs strongly ERK activation 
in response to LPS and a partial decrease is observed by stimulation with Pam3CSK4 and FSL-1. ERK 
activation by FSL1, which occurs at 3 and 10 min, is inhibited by approx. 33% (Fig. 12B). These results 
imply that Ras is a common upstream mediator for ERK activation by TLR4 and TLR2 ligands and 
TLR2 ligands, mainly FSL-1 partially activate ERK through PKCζ kinase. Therefore, these results 
show that in response to TLR2 ligands a TAK1-Ras dependent but MEK-independent pathway, 
together with PKCζ activity, contribute to ERK activation in the Raw264.7 cell line. 
Fig. 11 PD98059 inhibitor downregulates ERK activation in BMDM, regardless of the stimuli.  
Bone marrow-derived macrophages were pretreated with 50 µM PD98059 (“PD”) for 30 min. Cells were left unstimulated 
(c) or stimulated with LPS (100 ng/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min. A representative experiment is 
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Fig. 12 ERK activation by TLR2 ligands is Ras-dependent and PKCζ –partially dependent in Raw264.7 cells.  
Cells were pretreated with A) 10 µM Manumycin (“Ras inhibitor”); B) with 10 µM PKCζ inhibitor (PKCζ) for 30 min. Cells 
were left unstimulated (c) or stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 
and 60 min. A representative experiment is shown of two experiments. Graphics show quantification of band intensities of 
the upper western blots. All densitometry values of the p-ERK 1/2 band were normalized to the total ERK 1/2 protein. Data 





4.1.2.3 p38 activation is dependent of an autophosphorylation mechanism in the 
Raw264.7 cell line but not in primary macrophages 
The MAP kinase p38 activation is well described to be mediated by the classical TAK1-MEK3/6 
pathway in response to TLR ligands. However, a study using a human B cell line describes that LPS 
induces p38α by an autophosphorylation mechanism dependent of TAB1 kinase, which does not occur 
in the presence of TLR2 ligand lipoproteins (Ge et al., 2002). Considering this, we decided to 
investigate the effect of p38 inhibition upon stimulation with TLR4 and TLR2 ligands. For this 
experiment, Raw264.7 cells were stimulated with LPS, Pam3CK4 and FSL-1 in the absence or 
presence of a p38 inhibitor (SB203580) and p38 phosphorylation was determined by WB. Cells 
stimulated with LPS exhibited p38 activation mainly at 30 and 60 min and the presence of p38 inhibitor 
fully impaired the phosphorylation of this kinase. However, cell treatment with these inhibitors only 




Fig. 13 p38 activation is dependent of an autophosphorylation mechanism in the Raw264.7 cell line  
Raw264.7 cells were pretreated with A) 10 µM SB203580 and B) 1 µM of SB239063. Cells were left unstimulated (c) or 
stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min. Graphics show 
quantification of band intensities of the upper western blot. All densitometry values of the p-p38 band were normalized to the 






To confirm this result, another p38 inhibitor, SB239063 was also tested and the same result was 
obtained (Fig. 13B). In peritoneal macrophages, p38 phosphorylation state was not altered in the 
presence of the inhibitor, regardless of the stimulus (Fig. 14). 
 
 
This data demonstrates that LPS and at some extent Pam3CSK4 and FSL-1 induce p38 by an 
autophosphorylation mechanism, only observed in the Raw264.7 cell line. 
These results demonstrate that: (i) Raw264.7 cell line, but not primary macrophages, activate different 
upstream mediators of p38 and ERK signaling, which is dependent of the initial stimulus; (ii) TLR4 
and TLR2 differential kinetic signaling cannot be explained by differences on the upstream signaling 
cascades, at least in primary macrophages.  
Fig. 14 p38 phosphorylation is not affected by the inhibitor SB203580 in peritoneal macrophages. 
Peritoneal macrophages were pretreated with 10 µM SB203580. Cells were left unstimulated (c) or stimulated with LPS (100 
ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min. At each time point, cells were lysed, and the 
cell lysate was subjected to immunoblotting. Graphics show quantification of band intensities of the upper western blot.  All 
densitometry values of the p-p38 band were normalized to the total p38 protein. Data are representative of two independent 





4.1.3 MKP-1 role in MAPKs de-activation and inflammatory response by TLR4 and 
TLR2 ligands 
4.1.3.1 MKP-1 exhibits different activation and regulation kinetics by TLR4 and TLR2 
activation 
Previous results confirmed that MAPKs activation occurs earlier in response to TLR2 ligands 
compared to LPS. Furthermore, p38 and ERK phosphorylation induced by TLR2 declines faster, at 30 
and 60 min compared with the TLR4 ligand LPS, which occurs after 60 min (Fig. 2A and B). To 
understand the cause of these differences on p38 and ERK dephosphorylation, we sought to understand 
the possible role of phosphatases, more specifically MKP-1. This phosphatase was described to be 
induced and stabilized through phosphorylation by ERK in LPS-stimulated cells. Moreover, MKP-1 
has higher affinity to dephosphorylate p38 and JNK rather than ERK. (Brondello et al., 1999). 
Stimulation of Raw264.7 cells and peritoneal macrophages with the TLR ligands exhibit MKP-
1induction (Fig. 15A). In response to LPS, MKP-1 was induced at 60 min after stimulation, whereas 
in response to TLR2 ligands, mainly FSL-1, MKP-1 was detected earlier, at 30 min. A similar kinetic 
pattern was observed for MKP-1 transcription, however in peritoneal macrophages MKP-1 mRNA 
levels started to decay at 60 min (Fig. 15B). This data indicates that TLR2 ligands induce MKP-1 
transcription and expression earlier compared to the TLR4 ligand LPS.  
Since MKP-1 protein was reported to be stabilized by phosphorylation, increasing its half-life, protein 
and mRNA levels were quantified at later time points (Fig. 15C, left panel). LPS stimulation induced 
MKP-1 transcription at 2 hours followed by a decrease at 4 hours and reaching the basal levels at 6 
hours after stimulation (this is in accordance with a previous published work) (Crowell 2014). Strong 
protein levels were observed for MKP-1 at 2 hours in LPS-stimulated cells and at 4 and 6 hours after 
stimulation, some MKP-1 protein maintains stabilized (Fig. 15C, right panel). This shows that although 
MKP-1 transcription declines after 6 hours of stimulation, some protein is still present at this time 
point. On the other hand, when activated by TLR2 ligands, MKP-1 transcription is rapidly declined 
after 2 hours of stimulation. Nonetheless, at a protein level, we still observe a strong MKP-1 band for 
Pam3CSK4 at 2 hours of stimulation, but fainter in response to FSL-1. This indicates that in 
Pam3CSK4 and mainly FSL-1-stimulated cells, the duration of MKP-1 activation was lower compared 
to LPS-stimulated macrophages. In summary, these results show that MKP-1 transcription and 





Since previous published data (Chen et al., 2002) describes that MKP-1 activation is induced by ERK, 
inhibition of ERK and p38 was performed to evaluate whether MKP-1 expression is affected 
differentially via TLR4 and TLR2 activation. Raw264.7 cells stimulated with LPS show a complete 
abrogation on MKP-1 expression in the presence of ERK inhibitor, as well as a significant abrogation 
in the presence of p38 inhibitor (Fig. 16A). Thus, ERK and in part, p38 contribute for MKP-1 induction 
in response to LPS. MKP-1 expression was impaired in the presence of ERK inhibitor, but not affected 
when treated with SB203580, in response to Pam3CSK4 and FSL-1. Therefore, TLR2 ligands, mainly 
FSL-1 induced MKP-1 expression mediated mainly by ERK, whereas TLR4 activated MKP-1 was 
mediated primarily by ERK, with p38 playing a minor role. On the other hand, peritoneal macrophages 
treated with the TLR2 ligands showed a complete downregulation of MKP-1 expression in the presence 
of both inhibitors (Fig. 16B).  
B A 
C 
Fig. 15 MKP-1 exhibits different activation and regulation kinetics by TLR4 and TLR2 activation.  
A) Raw264.7 cells and peritoneal macrophages were left unstimulated (c) or stimulated with LPS (100 ng/mL), Pam3CSK4 
(1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 30 and 60 min. B) MKP-1 mRNA levels after cell stimulation with the three 
ligands at 30 and 60 min. C) Peritoneal macrophages stimulated at later time points as indicated by LPS, Pam3CSK4 and 
FSL-1. MKP-1 mRNA levels and protein were measured by qPCR and WB.  Data are representative of two independent 





4.1.3.2 MKP-1 phosphatase controls p38 but not ERK phosphorylation in response to 
TLR2 stimulation 
Previous data demonstrated that MKP-1 controls p38 activation in response to TLR4 activation (Chi 
et al., 2006; Zhao et al., 2006). Therefore, the MKP-1 role in MAPKs activation in response to FSL-1 
was addressed. WT and MKP1-deficient macrophages were treated with FSL-1 for 1 hour. 
Macrophages deficient in MKP-1 exhibited a prolongation p38 phosphorylation but not for ERK 
comparing with WT (Fig. 17). Therefore, besides TLR4, MKP-1 will preferably regulate p38 
phosphorylation in response to TLR2/6 stimulation. 
B 
A 
Fig. 16 MKP-1 induction is mediated by p38 and ERK in primary macrophages. 
A) Raw264.7 cells were pretreated with 10 µM FR180204 (“FR”) or 10 µM SB203580 (“SB”). Cells were left 
unstimulated (c) or stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) at 3, 10, 
30 and 60 min. B) Peritoneal macrophages were pretreated with the same inhibitors and then stimulated with 
Pam3CSK4 and FSL-1 for 30 and 60 min. Images are representative of two independent experiments.   
Fig. 17 WT and MKP-1 KO peritoneal macrophages were left unstimulated (c) or stimulated FSL-1 (100 ng/mL) at 3, 10, 30 





4.1.3.3 MKP-1 differentially controls pro and anti-inflammatory cytokines in response 
to TLR2 ligands 
Since MKP-1 expression is differentially regulated via TLR4 and TLR2 activation, and previous 
studies reported a role of MKP-1in cytokines regulation induced by LPS (Chi et al., 2006; Zhao et al., 
2006), the effect of this phosphatase on TLR2-mediated cytokine induction was studied at later time 
points (Fig. 18). 
Fig. 18 MKP-1 differentially regulates pro and anti-inflammatory cytokine’s expression. 
WT and MKP-1 KO peritoneal macrophages were left unstimulated (Ctrl) or stimulated with LPS (100 ng/mL), Pam3CSK4 
(1 µg/mL) and FSL-1 (100 ng/mL) at 4, 8, and 24 hours. At each time point, cell supernatant was collected, and cytokines 





Stimulation of WT and MKP-1 deficient peritoneal macrophages with TLR4 and TLR2 ligands at 4, 8 
and 24 hours was carried out, followed by cytokine´s quantification. In the absence of MKP-1, a 
decrease in TNF-α, IL-12p40 and IL-6 levels was observed over time, but the effect was stronger in 
response to TLR2 ligands stimulation at 8 and 24 hours, compared to LPS. On the other hand, IL-10 
levels increased at 8 and 24 hours in MKP-1 deficient macrophages stimulated with LPS, whereas in 
response to TLR2 ligands the IL-10 levels were similar to WT cells (Fig. 18). This indicates that MKP-
1 upregulates pro-inflammatory cytokines, which is more pronounced by TLR2 activation, but 
regulates IL-10 expression at later stages of the inflammation process. 
4.1.4 p38 is critical for later IL-10 expression by TLR2 ligands 
Published data describes that IL-10 expression is dependent of p38 activation in response to LPS (Kim 
et al., 2008). Thus, the next step was to investigate the effect of p38 and ERK inhibition in the 
cytokine’s induction by the TLR2 ligands. A time-course kinetics was performed to determine the 
changes of cytokine levels in Raw2634.7 cells pretreated with SB203580 or FR180204 and stimulated 
with TLR4 or TLR2 ligands for 4, 8 and 24 hours (Fig. 19). Stimulation with TLR2 ligands gave a 
similar pattern for TNF-α induction, however IL-6 levels were lower at earlier time points compared 
to the levels induced by LPS. Nevertheless, at 24 hours, p38 has a regulatory role in IL-6 induction in 
response to Pam3CSK4 and FSL-1, similarly observed in response to LPS. However, IL-10 levels are 
highly increased at 24 hours in response to TLR2 ligands and fully dependent of p38.  The effect of 
p38 and ERK inhibition on cytokine’s expression was further evaluated in peritoneal macrophages 
pretreated with p38 and ERK inhibitors and stimulated with TLR ligands for 24 hours. The pro-
inflammatory cytokines TNF-α, IL-6 and IL-12 were not apparently affected in the presence of the p38 
inhibitor, however (Fig. 20A). On the other hand, IL-10 levels were strongly decreased by p38 
inhibition. A similar pattern was observed for the cytokine transcription levels in stimulated-peritoneal 
macrophages (Fig. 20B). These results imply that ERK and p38 are important for pro-inflammatory 
cytokines induction at early time points of inflammation, whereas p38 contributes for later anti-






Fig. 19 p38 contributes for later IL-10 production in response to TLR ligands in Raw264.7 cells. 
Raw264.7 cells were pre-treated with 10 µM SB203580 or 10 µM of FR180204 for 30 min and then stimulated with LPS 
(100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) for 24 hours. Cytokines mRNA expression was assayed by 
quantitative RT-PCR, normalized to GAPDH, and presented relative to unstimulated cells. Protein levels were also measured 









Fig. 20 p38 contributes for later IL-10 production in response to TLR ligands, in peritoneal macrophages.   
Peritoneal macrophages were pre-treated with 10 µM SB203580 or 10 µM FR180204 for 30 min and then stimulated with 
LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) for 24 hours. A) Cytokine mRNA levels and B) Cytokine 
protein levels were measured by qPCR and ELISA. Data are representative of three independent experiments (mean ± SEM.) 





4.2 CHAPTER 2: TRIF-IFN-β signaling dependence in TLR2 inflammatory responses 
4.2.1 TLR2 ligands induce type I interferon in an endocytosis-dependent manner 
Over the years, it had been suggested that only TLR4 and the endosomal receptors TLR3 and TLR7 
signaling could activate the TRIF-IFN-β signaling pathway.  However, recent published work from 
Dietrich et al and Stack et al show that TLR2 ligands are also capable of inducing the mediator IFN-β 
in bone marrow-derived macrophages (Dietrich et al., 2010; Stack et al., 2014). Given this, type I IFN 
activation by TLR2 ligands was explored in other macrophages subtypes, in this case peritoneal 





Fig. 21 TLR2 ligands induce IFN-β in the Raw264.7 cell line and in peritoneal macrophages.  
A) Raw264.7 cells were stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) for the different 
times indicated. B) WT peritoneal macrophages were stimulated with the three ligands for 2 and 6 hours. C) WT and TLR2 
KO peritoneal macrophages were stimulated with the three ligands for the different times indicated. IFN-α/β mRNA levels 
were assayed by quantitative RT-PCR. The results are shown as mean ± SEM of two independent experiments (* p˂0.05, ** 





A time course analysis was performed to determine the kinetics of IFN-β gene induction by stimulation 
of Raw264.7 cells with LPS, Pam3CSK4 and FSL-1 for 1, 3 and 6 hours. LPS induced transcription of 
IFN-β, which increased along the time and at 6 hours IFN-β levels are 4 times more compared to IFN-
β induced by TLR2 ligands (Fig. 21A).  On the other hand, the isotype IFN-α is not induced by TLR4 
and TLR2 ligands (Fig. 21B). Moreover, stimulated peritoneal macrophages induce IFN-β levels at 6 
hours in response to Pam3CSK4 and FSL-1 and this IFN-β was specific to TLR2 receptor activation 
(Fig. 21C).  This data suggests that peritoneal macrophages and mouse Raw 264.7 macrophage cell 
line have a similar response regarding type I IFN induction by TLR2 activation. It is described that 
LPS-mediated IFN-β induction requires the internalization of TLR4 receptor. The next step was to 





Fig. 22 IFN-β induction by Pam3CSK4 and FSL-1 requires TLR2 internalization  
A) Raw264.7 cells were pretreated with 80 µM dynasore, 10 µg/mL chlorpromazine (CPZ) and 100 µM chloroquine. Cells 
were left unstimulated (Ctrl) or were stimulated with Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) for 6 hours. The results 
are shown as mean ± SEM of two independent experiments. B) Peritoneal macrophages were pretreated with 80 µM dynasore 
and stimulated with Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) for 6 hours. The data is shown as mean ± SEM of three 
independent experiments (* p˂0.05, ** p˂0.01, and *** p˂0.001). C) IFN-β expression from peritoneal macrophages was 





Raw264.7 cells were pretreated with three different endocytic inhibitors, dynasore, chlorpromazine 
and chloroquine. The first two inhibitors disrupt clathrin-dependent endocytosis, although dynasore, a 
dynamin GTPase inhibitor, is also described to disrupt clathrin non-dependent endocytic pathways. 
Chloroquine prevented the endosome acidification and subsequent fusion with the lysosomes.  The 
presence of the three inhibitors severely impaired TLR2-driven IFN-β, suggesting that IFN-β was 
triggered from acidified endosomal compartments (Fig. 22A). Treatment of peritoneal macrophages 
with dynasore also affected IFN-β production induced by TLR2 ligands (Fig. 22B and 22C). Since 
IFN-β production in response to TLR2 ligands is dependent of an endocytosis process, TLR2 






Fig. 23 Pam3CSK4 and FSL-1 induce TLR2 internalization.  
A) Raw264.7 cells were left unstimulated (Ctrl) or stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 
ng/mL) for 3, 10, 30 and 60 min. Cell surface expression levels of TLR4 or TLR2 are represented as (MFI) mean fluorescence 
intensity. B) Raw264.7 cells were left unstimulated (Control) or were stimulated with Pam3CSK4 (1 µg/mL) and FSL-1 (100 






Cells were stimulated with LPS and TLR4 uptake was addressed as a reference. Upon stimulation with 
LPS, TLR4 cell surface levels increased at 3 min and reached a peak at around 10 min, followed by 
internalization after 30 min (Fig. 23A). TLR2 ligands, mainly Pam3CSK4 induced a slight but faster 
increase in TLR2 surface expression followed by a rapid uptake 3 min after stimulation. After 10 min 
a slow increase of TLR2 levels at the surface extended along the time. In addition, through 
immunofluorescence, Pam3CSK4 and FSL-1-stiumlated cells showed higher TLR2 localization at the 
cell surface, as well as some present in the cytoplasm, compared with non-stimulated cells (Fig. 23B). 
Therefore, as it occurs for TLR4, TLR2 is also internalized upon stimulation, however this process 
occurs earlier and at a lesser extent as for TLR4. 
4.2.2.1 TLR2 ligands activate IRF3, IRF7 and IFN-β mediated in part by TRIF 
The transcription of IFN-β depends on the activation of IRFs (interferon regulatory factors). IRF3 and 
IRF7 have been implicated in the activation of type I IFN genes in response to TLR4, TLR3 and TLR9, 
respectively. Previous studies support that IFN-β by TLR2 ligands is IRF7-dependent in BMDMs 
(Dietrich et al., 2010; Nilsen et al., 2015; Stack et al., 2014) and that FSL-1 induces IRF3 and IRF7 
phosphorylation in the Raw264.7 cell line. However, so far it was not addressed the activation of IRF3 
or IRF7 by TLR2 signaling in peritoneal macrophages. Our results show that LPS induces IRF3 
activation in peritoneal macrophages, observing higher levels of phosphorylation at 30 and 60 min 
(Fig. 24A). Pam3CSK4 activates higher p-IRF3 levels mainly at 30 min and FSL-1induces IRF3 
phosphorylation earlier, however the phosphorylation levels obtained are lower compared to LPS and 
Pam3CSK4 stimulation. Thus, FSL-1 is a weaker IRF3 inducer compare to the other ligands. In 
addition, a similar pattern was observed for IRF7 activation in response to LPS, observing higher levels 
of IRF7 phosphorylation at 60 min. On the other hand, Pam3CSK4 showed high activation of IRF7 at 
30 min and FSL-1 showed higher levels of phosphorylated IRF7 at 3, 10 and 30 min compared with 
the other ligands. Therefore, FSL-1 exhibits a weaker activation of IRF3 phosphorylation but a faster 
induction of IRF7 phosphorylation. To ensure these observations were not due to possible LPS 
contamination in TLR2 ligand preparations, the same experiment was performed in TLR4 KO 
peritoneal macrophages (Fig 24B). IRF3 and IRF7 phosphorylation was impaired in LPS-stimulated 
cells deficient in TLR4, but detectable in response to TLR2 ligands, thus confirming a TLR2 specific 
response. Furthermore, Raw264.7 cells stimulated with Pam3CSK4 and FSL-1 ligands induced IRF3 
phosphorylation in Ser 396 at 30 min, although to a lesser extent compared to LPS stimulation, which 
was observed at 60 min (Fig. 24C). Therefore, in addition to LPS, TLR2 ligands can induce the 
phosphorylation of IRF3 and IRF7 in primary macrophages and in the Raw264.7 cell line, however, 







Furthermore, to determine the endocytosis dependency for IRF3 and IRF7 activation by TLR2 ligands, 
WT peritoneal macrophages were pretreated with dynasore (Fig 25). IRF3 and IRF7 phosphorylation 
was blocked by dynasore in response to LPS. In Pam3CSK4 and FSL-1-stimulated cells, IRF3 and 
IRF7 phosphorylation was impaired by dynasore, mainly at 10 and 30 min. Thus, similar to TLR4, the 






Fig. 24 TLR2 ligands activate IRF3 and IRF7 in peritoneal macrophages and in the Raw264.7 cell line.  
A) WT peritoneal macrophages were left unstimulated (c) or stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and 
FSL-1 (100 ng/mL) for 3, 10, 30 and 60 min. Graphics show quantification of band intensities of the upper western blots. The 
values of p-IRF3 and p-IRF7 bands were normalized to the total IRF3 and IRF7 protein respectively. Data are representative 
of three independent experiments (mean ± SEM.) (*p ˂ 0.05, **p ˂ 0.01, and ***p ˂ 0.001). B) TLR4 KO peritoneal 
macrophages were left unstimulated (c) or stimulated with LPS (100 ng/mL), Pam3CSK4 (1 µg/mL) and FSL-1 (100 ng/mL) 
for 3, 10, 30 and 60 min. Images are representative of two independent experiments. C) Raw264.7 cells were unstimulated 






The activation of these transcription factors was also evaluated in bone marrow-derived macrophages. 
LPS induced IRF3 and IRF7 activation (Fig. 26), however, IRF3 phosphorylation was weakly induced 
by Pam3CSK4 and FSL-1. In addition, LPS induced IRF7 phosphorylation mainly at 60 min, whereas 
IRF7 phosphorylation is observed earlier at 10 min and maintains up to 60 min in response to TLR2 
ligands. Furthermore, TRIF dependency for IRFs activation was evaluated. In TRIF-deficient 
macrophages, IRF3 and IRF7 phosphorylation was abrogated in response to stimuli. Thus, this data 
indicates that activation of these transcription factors is dependent of TRIF adaptor.   
Previous studies reported that TLR4 activation induces IFN-β expression via TRIF signaling (Kagan 
et al., 2008). Therefore, the role of TRIF in IFN-production mediated by TLR2 ligands was accessed 
(Fig. 27).  LPS-induced IFN-β transcription and expression was fully abolished in TRIF KO 
macrophages at 3 and 6 hours. In contrast, IFN-β was partially impaired in response to Pam3CSK4 at 
3 and 6 hours, and a complete downregulation was observed for FSL-1-induced IFN-β at 6 hours (Fig. 
27A and 27B). These results imply that IFN-β induction by TLR2 ligands is driven in part by TRIF 
activation and other pathways are likely contributing for the IFN expression at earlier stages (≤ 3 
hours). 
Fig. 25 TLR2- induced IRF3 and IRF7 phosphorylation is dependent of receptor endocytosis. 
Peritoneal macrophages were pretreated with 80 µM dynasore (“Dyn”) for 30 min and then stimulated with LPS and TLR2 
ligands. Graphics show quantification of band intensities of the upper western blots. The values of p-IRF3 and p-IRF7 bands 
were normalized to the total IRF3 and IRF7 protein respectively. Data are representative of two independent experiments 








Fig. 27 TLR2 ligands induce IFN-β mediated in part by TRIF activation.  
A) WT and TRIF KO bone marrow-derived macrophages were stimulated with LPS, Pam3CSK4 and FSL-1 for 3 and 6 hours 
and cytokine’s mRNA transcription was assayed by quantitative RT-PCR. The results are shown as mean ± SEM of two 
independent experiments (* p˂0.05, ** p˂0.01, and *** p˂0.001). B) IFN-β expression was also measured by ELISA. The 
graphic shows the results of one experiment 
Fig. 26 TLR2 ligands activate IRF3 and IRF7 in bone marrow-derived macrophages, mediated by TRIF activation.  
WT and TRIF KO bone marrow-derived macrophages were left unstimulated (C) or stimulated with LPS, Pam3CSK4 and 







4.2.2.2 TRIF-IFN-β signaling pathway contributes to macrophage inflammatory 
response via TLR2 activation 
TRIF-IFN-β signaling mediated by TLR4 is described to be important for the induction of pro and anti-
inflammatory cytokines. Therefore, the involvement of the TRIF pathway in the regulation of TLR2-
induced cytokines was determined (Fig. 28). 
 
 
Fig. 28 TLR2 ligands induce pro-inflammatory cytokines, in part, mediated by TRIF activation. 
WT and TRIF KO bone marrow-derived macrophages were stimulated with LPS, Pam3CSK4 and FSL-1 for 8 and 24 hours. 
Protein levels were measured by ELISA. The results are shown as mean ± SEM and are representative of three independent 





LPS-stimulated TRIF KO macrophages displayed fully downregulation of the cytokines IL-12p40, IL-
16 and TNF-α, while IL-10 was partially affected at 8 hours, and no differences were observed at 24 
hours relatively to the WT cells. Moreover, Pam3CSK4 and FSL-1 responses in TRIF deficient 
macrophages were similar between both.  
Specifically, TNF-α and mainly IL-12p40 induction was strongly impaired in TRIF KO macrophages, 
whereas IL-6 production was partially impaired and IL-10 was not affected. Therefore, at later stages 
of inflammation, unlike LPS, which strongly depends in the TRIF pathway for pro-inflammatory 
cytokine induction, TLR2 ligands depend mostly of TRIF for TNF-α and IL-12p40 induction. 
To determine whether IFN-β per se contributes for TLR2-mediated cytokine induction, Raw264.7 cells 
were pretreated with a blocking antibody against IFN-β and consequently stimulated with TLR2 
ligands (Fig. 9). IL-12 mRNA was strongly inhibited in the presence of the antibody, whereas IL-6 and 
IL-10 where only partially decreased. Therefore, TLR2-mediated TRIF-IFN-β signaling pathway plays 
an important role in late inflammatory response, mainly for IL-12p40 induction. 
4.2.2 Effect of TLR2 ligand FSL-1 administration in neonatal listeriosis  
Previous studies demonstrate that the PGN deacetylation of Listeria monocytogenes by the deacetylase 
pgdA avoids its degradation and the release of PAMPs (PGN, lipoproteins, LTA) recognized by TLR2 
and NOD1/NOD2. Indeed, Listeria pgdA mutants induced a stronger IFN-β production compared to 
the WT strain, which was shown to be mediated by TLR2-TRIF signaling (Aubry et al., 2012; Boneca 
et al., 2007). Moreover, the timing of IFN-β production in response to Listeria is determinant to control 
the bacteria infection (Pontiroli et al., 2012).  Our results show that TLR2 ligands can induce IFN-β 
expression and a previous study reported that diacylated lipoproteins are found in Listeria 
monocytogenes cell wall (Kurokawa et al., 2012). Therefore, since FSL-1 is a diacylated lipopeptide, 
a mouse model of neonatal listeriosis was developed to study the immunomodulatory and protective 
Fig. 29 IFN-β contributes to macrophage inflammatory response via TLR2 activation.  
Raw264.7 cells were stimulated with Pam3CSK4 or FSL-1 for 24h in the presence of Ctrl Ab or 25 µg/mL anti-IFN-β. IL-
12, IL-6 and IL-10 transcription was measured by qPCR. Results are shown as mean ± SEM of two independent experiments 





effect of FSL-1 in Listeria infection (Fig 30). Pregnant mice were challenged intravenously with L. 
monocytogenes and with FSL-1 simultaneously. Four-day old neonates were chosen as they correspond 
to 1-month age in human neonates.  
 
 
Physical appearance and motility of neonates from infected mothers and infected and treated mothers 
was monitored during the birthday and four days after birth (Fig. 31). Previous data demonstrate that 
in the mouse model of neonatal listeriosis, infected mothers give birth to 2-4 pups whereas non-infected 
mothers present 6-9 pups per litter (Calderon-Gonzalez et al., 2017). In our hands, infected mothers 
gave birth to 4 pups whereas treated mothers gave birth to 5 pups. At day 4, the neonates survived from 
infected mothers as well as from treated mothers. FSL-1 treatment showed no improved effect in the 
birth number of neonates from infected mothers. However, at day 4, white spots due to lack of 
pigmentation and reduced movement were noticed in neonates from infected mothers, whereas these 
symptoms where not detected in neonates from treated mothers (Fig. 31A). Moreover, neonates from 
infected mothers showed lack of brain integrity compared to neonates from treated mothers (Fig. 31B). 
In addition, infected mothers showed fetal reabsorptions in the uterus, which were not visible in treated 
mothers (Fig. 31C). These data indicate that albeit FSL-1 treatment does not prevent the stillbirth in 
infected mothers, it confers some preventive effect on neonate brain disease. 
 
Fig. 30 Mouse model of neonatal listeriosis.  
Pregnant mice were inoculated with Listeria monocytogenes during gestation phase and FSL-1 ligand was administered 





4.2.2.1 FSL-1 treatment decreases organ bacteria load in neonates and mothers  
Reported studies demonstrate that TLR2-deficient mice show increased susceptibility to Listeria 
infection (Torres et al., 2004). In addition, our results demonstrated that FSL-1 administration in 
pregnant mice partially prevents the common clinical symptoms in neonatal listeriosis. Therefore, the 
effect of FSL-1 in organ bacterial clearance in the livers, spleen and brain of infected, treated mothers 
and neonates was analyzed (Fig. 32). Treated mothers displayed a 10 and 15-fold reduction of CFU 
counts in the liver and spleen respectively, compared to infected mothers. On the other hand, no 
difference in bacteria load was apparent in the liver of D4 neonates from infected and treated mothers.  
Neonates from treated mothers displayed a slight decrease in spleen bacteria load but the brain bacterial 
burden was reduced by 100-fold compared to neonates from infected mothers. These results 
demonstrate that the protective action of FSL-1 for both mothers and neonates Listeria infection is only 
partially due to the reduction of bacterial growth. This implies that additional mechanisms can 




Fig. 31 Physical appearance of neonates from Listeria infected mothers and FSL-1 treated mothers at birth (D0) and 
4 days after birth (D4). 
A) Comparison of D0 neonates and D4 neonates from infected and infected treated mothers for physical and motility 
appearance. B) Brains isolated from D4 neonates of infected and infected treated mothers C) Uterus appearance from infected 





4.2.2.2 FSL-1 treatment increases IFN-β expression in Listeria-infected neonate’s 
microglia 
Inflammatory cytokines such as IFN-γ, TNF-α and IL-12p40 produced by NK cells, macrophages and 
DCs are critical for controlling a primary L. monocytogenes infection (Edelson and Unanue, 2000). 
Therefore, the effect of FSL-1 treatment in cytokine expression during the infection in mothers and 
neonates was evaluated (Fig. 33).  
Serum TNF-α and IFN-γ levels are similar from infected and treated mothers and TNF-α levels are 
higher compared to the control group, whereas IL-6 and IL-10 are reduced compared to the control 
group. On the other hand, MCP-1, a chemokine that recruits monocytes and dendritic cells to the sites 
of infection, showed high expression levels in infected mothers compared to non-infected cells and 
FSL-1 treatment increased its production. On the other hand, microglia of D4 neonates from infected 
mothers exhibited very low levels of IL-10, IL-6 but some expression of IFN-β, which was higher in 
neonates from treated mothers. These data correlate with the previous results where TLR2 ligands 
Fig. 32 Bacterial burden in distinct organs of mothers and D4 neonates. 
Organs were extracted (2 mothers or 2 neonates per condition), homogenized and pooled for CFU counting. Results are 
expressed as CFUs/mL.    
Fig. 33 FSL-1 treatment increases IFN-β expression in infected neonate’s microglia.  
Cytokine expression levels in serum from infected and treated mothers (1 mother per condition) and from D4 neonates’ 





induce IFN-β in macrophages. Overall, these results imply that in vivo FSL-1 treatment favors a Th1 
response in Listeria infected mothers and particularly an increase in IFN-β expression in infected 
neonate’s microglia.  
4.2.2.3 TLR2 ligands induce the expression of IL-12 and IFN-β in Listeria-infected 
dendritic cells 
In view of the FSL-1 beneficial role in the prevention of neonatal listeriosis symptoms and the IFN-β 
increment in the microglia of neonates from treated mothers, the modulatory effect of TLR2 ligands 
on cytokine’s expression was further explored in Listeria-infected dendritic cells. One hour after 





Fig. 34 TLR2 ligands increase Th1 cytokines IL-12 and IFN-β in Listeria-infected dendritic cells 
Dendritic cells were infected with Listeria for 1 hour (infected) or infected and treated with: A) Pam3CSK4, FSL-1and 
IV1303; B) incremental doses of recombinant mouse IFN-β (5, 10 and 20 ng/mL). All treatments were performed for 24 
hours and cell supernatants were used for cytokine quantification by CBA. Results are shown as mean ± SEM of three 





IV1303 is a compound previously described as an adjuvant that elicits a protective Th1 response in 
neonatal listeriosis (Calderon-Gonzalez et al., 2017). Therefore, this compound was used as reference. 
Infected DCs showed strong expression levels of TNF-α and IL-6 compared to non-infected cells (Fig. 
34A). These cytokines together with IL-12 are determinant for macrophage activation and increase of 
their bactericidal role. Moreover, IL-12, IL-10 and IFN-β expression was also observed in infected 
DCs. TLR2 ligands treatment showed increased levels of TNF-α and IL-6 and a similar pattern was 
observed in response to the compound IV1303, compared to infected non-treated DCs. In addition, 
infected DCs treated with IV1303 presented higher IL-10 expression levels compared to TLR2 ligands. 
On the other hand, TLR2 ligands administration incremented IL-12 and IFN-β expression in infected 
cells which was lower in response to IV1303. These results indicate that IV1303 and TLR2 ligands 
improve Th1 responses due to higher expression levels of pro-inflammatory cytokines (TNF-α, IL-6 
and IL-12) However, TLR2 ligands differ due to their higher capacity of inducing IFN-β production 
To determine the IFN-β role per se in cytokine regulation, infected DCs were treated with incremental 
doses of rIFN-β (Fig. 34B). Pro-inflammatory cytokines were found to be dose-dependently increased 
by an exogenous source of IFN-β, whereas IL-10 expression decreased. This result indicates that IFN-
β contributes for pro-inflammatory cytokines induction and downregulates the expression of the anti-
inflammatory cytokine IL-10. Given the positive effect of exogenous IFN-β in pro-inflammatory 
Fig. 35 IFN-β is involved in TLR2- mediated IL-12 induction and IL-10 regulation in Listeria-infected dendritic cells.  
Dendritic cells were left unstimulated (Ctrl) or were stimulated with Pam3CSK4, FSL1 and IV1303 for 24h in the presence 
of Ctrl Ab or 25 µg/mL anti-IFN-β. Cytokine’s expression was measured by CBA. The data is representative of three 





cytokines and the regulation of IL-10 expression in infected dendritic cells, it was further studied 
whether TLR2-induced IFN-β is determinant for the modulatory effect of the cytokines induced in 
response to TLR2 ligands, during Listeria infection (Fig 35).  
Infected DCs were pre-treated with a blocking antibody against IFN-β and subsequently stimulated 
with Pam3SCK4, FSL and IV1303 for 24 hours. Neutralization of IFN-β induced by TLR2 ligands 
partially downregulates IL-6 and TNF-α, whereas IL-10 expression is not affected. A similar result is 
observed in response to IV1303. On the other hand, IL-12 cytokine was found to be fully dependent 
on IFN-β induced by TLR2 ligands and IV1303 in infected dendritic cells. Altogether, the results 
indicate that TLR2 ligands provide a beneficial effect in neonatal listeriosis, in part by controlling the 
organ’s bacterial growth and by eliciting a Th1 response with high induction of IFN-β in neonate’s 





4.3 CHAPTER 3: Ochrobactrum intermedium LPS induces TLR4 and TLR2 
heterodimerization 
4.3.1 O. intermedium LPS induces an inflammatory response mediated by TLR4 and 
TLR2 receptors in primary mouse macrophages 
Some type of LPS, termed atypical LPS are described to be dependent of TLR2 to induce inflammatory 
responses rather than TLR4 (Burns et al., 2010; Girard et al., 2003). In addition, previous studies 
performed in our laboratory indicate that Ochrobactrum intermedium LPS (O. intermedium LPS) 
requires the presence of both TLR4 and TLR2 receptors to induce a cytokine response in primary 
mouse macrophages. To confirm this, WT, TLR2 and TLR4 KO peritoneal macrophages were 
stimulated with two different doses of this LPS and compared with the controls: E. Coli LPS (TLR4 
ligand) and FSL-1 (TLR2 ligand) (Fig. 36).  
Fig. 36 O. intermedium LPS gives a weak inflammatory response, mediated by TLR2 and TLR4. 
 WT, TLR2 KO and TLR4 KO peritoneal macrophages were left unstimulated (Ctrl) or were stimulated with E. coli LPS 
(100 ng/mL), Pam3CSK4 (1 µg/mL), FSL-1 (100 ng/mL) and O. intermedium LPS (1 and 10 µg/mL) for 24 hours. Cytokines 
mRNA levels were measured by qPCR. The data shown is representative of two independent experiments (mean ± SEM) (*p 





WT macrophages stimulated with O. intermedium. LPS showed a weaker induction of cytokines 
compared to E. Coli LPS. O. intermedium LPS only achieved similar cytokine levels to E. coli LPS at 
a 100-fold dosis of 10 ug/mL. Moreover, this LPS showed dependency on TLR4 and TLR2 in order to 
induce cytokines. IL-12, IL-6 and in part TNF-α were dependent on TLR2 and TLR4 signaling, 
whereas IL-10 induction was mostly TLR2-dependent. In addition, NF-κB and MAPKs activation 
induced by O. intermedium LPS increases in a dose dependent manner, however the response was 
always much weaker compared to E. coli LPS (Fig. 37). Thus, O. intermedium LPS is a TLR4/TLR2-
dependent agonist. 
4.3.2 Ligand-protein docking studies to access the ability of O. intermedium LPS to bind 
to hTLR2/TLR4-MD-2 heterodimer 
4.3.2.1 Docking with the model hTLR2/TLR4-MD2 heterodimer and hTLR4/MD-2 
homodimer 
Since O. intermedium LPS is a TLR4 and TLR2-dependent agonist, the ability of this LPS to bind to a 
theoretical heterodimer formed by the human TLR2 and TLR4-MD2 receptors was explored by a 
molecular docking approach. The final structure of the hypothetical hTLR2/TLR4-MD2 heterodimer 
model  constructed is displayed (Fig. 38). 
 
 
Fig. 37 O. intermedium LPS weakly induces NF-қB and MAPKs activation.  
WT peritoneal macrophages were treated with E. coli LPS and four distinct doses of O. intermedium LPS for 30 min. NF-
қB and MAPKs activation was determined by Western Blot. Graphics on the right panel show quantification of band 
intensities of the western blot.  The values of p-ERK 1/2 and p-p38 bands were normalized to the total ERK 1/2 and p38 
protein, respectively and IκBα levels were normalized to actin. The data are representative of three independent experiments 






The O. intermedium LPS was divided in the different fragments, described in Material and Methods 
section. The importance of performing dockings with fragments is to minimize the atomic spatial 
energy. According to the literature and the crystal structure PDB ID 3FXI, E coli LPS accommodates 
five of its six lipid A chains inside the MD-2 pocket and the remaining chain is at the surface of MD-
2 in a molecular channel where it interacts with the partner TLR4 (Park et al., 2009) . Given this, it 
was explored the ability of O. intermedium LPS fragments (IV19, IV28 and IVcore) to bind to the MD-
2 pocket in the hTLR2/TLR4/MD-2 complex. From the docking calculations, favorable poses for the 
three fragments were found with predicted binding energies ranging from -6.8 to -6.6 and -7.3 to –6.9 





Fig. 38 A) 3D structure of hTLR2/TLR4/MD-2 heterodimer model in front view and upper view. TLR2 is represented in 
green and TLR4 and MD-2 in orange. B) Representation of the full O. intermedium LPS structure and the obtained 
fragments: the core saccharide (IV core), the fragment with the two fatty acid chains containing 12 and 16 carbons and the 
third 28 carbon acyl chain attached to C16 (IV28), the fragment containing the two lipid chains with 14 and 18 carbons 






The two lipid A fragments showed their three FA chains buried in the MD-2 pocket. The glucosamine 
phosphate group was interacting with the NH2 groups of Arg264 (Fig. 39A), which is the same residue 
that interacts with the glucosamine of the E. coli LPS in the hTLR4/MD-2 crystal structure (PDB ID 
3FXI). The core was near the entrance of MD-2 and the KDO I was spatially close to the glucosamine 
groups of the O. intermedium lipid A fragments (Fig. 39B). 
E. coli LPS recognition by hTLR4/MD-2 complex was previously described (Park et al., 2009). The 
inner core of E. coli LPS is composed of KDO I, KDO II and heptoses, and these sugars stablish 
determinant interactions with MD-2 (e.g. Ser 118, Lys 122) and TLR4 residues (e.g. Lys 341, Tyr 296, 
Asp 294). Thus, besides the E. coli lipid A, the core is also important for inducing the dimerization of 
hTLR4/MD-2 monomers. Therefore, O. intermedium LPS was docked in hTLR4/MD-2 homodimer 
and superimposed with the E. coli LPS to compare binding orientation and interactions of these LPSs 
with the two TLR4 monomers. The docked poses were favorable with predictive binding energies 
ranging from -6.2 to -6.9 kcal mol-1. The obtained binding poses showed that O. intermedium LPS FA 
chains were buried in the MD-2 pocket, however, the core saccharide dove towards TLR4*-TLR4 
interface (Fig. 40A). This is more evident when the docked pose O. intermedium LPS is superimposed 
with E. coli LPS in the hTLR4/MD-2 homodimer (Fig. 40B). Despite E. coli LPS core established 
determinant interactions with TLR4 residues (e.g. Tyr296, Asp294 and Arg264) as well as with TLR4* 
Fig. 39 View of the fragments IV28, IV19 and IVcore docked in the hTLR4/MD-2 pocket  
A) IV28 (in magenta) and IV19 (in cyan) docked in the TLR4/MD-2 pocket. B) Superimposition of the three fragments (IV 






(Gln436), these interactions were not detected with O. intermedium LPS (Fig. 40C and D). This results 
theoretically indicates that in contrast to E. coli LPS, O. intermedium LPS does not favor the formation 




Fig. 40 General view of O. intermedium LPS and E. coli LPS docked in hTLR4/MD-2 dimer  
A) Full O. intermedium LPS (in purple) conformation with the core diving towards TLR4*/TLR4 interface. B) E. coli LPS 
docked pose (in cyan) superimposed with O. intermedium LPS pose (in purple) in hTLR4/MD-2 dimer (hTLR4 and MD-2 
are in grey and hTLR4/MD-2* was omitted for clarity). The polar interactions established between C) O. intermedium LPS 
and D) E. coli LPS with TLR4* (brown), TLR4 (in orange) and MD-2 (on grey) residues are presented. (An asterisk 





Full O. intermedium LPS was docked in the hTLR2/TLR4/MD-2 heterodimer to explore possible 
theoretical binding modes. The docked poses were favorable with predictive binding energies ranging 







Fig. 41 General view of O. intermedium LPS and E. coli LPS docked in hTLR2/TLR4/MD-2 heterodimer  
A) O. intermedium LPS (in cyan) conformation with one FA chain protruding out of the MD-2 pocket. B) E. coli LPS docked 
pose (in cyan) was superimposed with O. intermedium LPS pose (in purple) in hTLR2/TLR4/MD-2 complex (hTLR4 and 
MD-2 are in grey and hTLR2 was omitted for clarity). The polar interactions established between C) O. intermedium LPS 
and D) E. coli LPS with TLR2 (green), TLR4 (in orange) and MD-2 (on grey) residues are presented. (TLR4 and MD-2 are 





The obtained binding poses showed that five FA chains of the LPS were buried in MD-2 pocket, 
remaining the sixth C12 chain on its surface (Fig. 41A). In this case, both LPSs showed their lipid A 
part accommodated in MD2-pocket. However, E. coli LPS core was diving towards TLR2/TLR4 
interface (Fig. 41A and B). The interactions of the E. coli LPS core with the TLR4 residues described 
in the hTLR4/MD-2 dimer (Tyr 296, Lys 341 or Asp294) are not observed in the presence of the hTLR2 
monomer (Fig. 41D). The TLR4 residues interacting with E. coli LPS core are nearer the TLR4 and 
TLR2 interface. This suggests that E. coli LPS does not favor the proximity of TLR4 and TLR2 
receptors. On the other hand, O. intermedium LPS core maintains interactions with TLR4 residues such 
as Tyr 296 and Arg264, as well as with TLR2 residues far from the interface region (Fig. 41C). This 
imply that O. intermedium LPS accommodates in the hTLR2/TLR4/MD-2 complex in such a way that 
could favor the dimerization of both receptors. The O. intermedium LPS poses obtained from the 
dockings performed in hTLR2/TLR4/MD-2 heterodimer and hTLR4/MD-2 homodimer hint that the 
core composition and/or structure of this LPS might favor the formation of a hTLR2/TLR4 complexes 
rather than TLR4 homodimers.  
The ability of O. intermedium LPS core to bind in the hTLR2 and TLR4 interface region was also 
investigated. The final docked poses gave favorable predicted binding energies, ranging from -7.2 to -
6.3 kcal mol-1 (Fig. 42). In this docking, more diversity in the binding poses was observed, where 
despite most of the poses were near the entrance of MD-2 pocket, some poses features the ligand in 
the upper region of the TLR2/TLR4 interface and towards TLR2 central domain. This was not observed 
with E. coli core, were all the docked poses in the heterodimer are located only near the MD-2 pocket 
(data not shown). 
 
The ability of O. intermedium LPS core to interact with hTLR2 interface in the hTLR2/TLR4/MD-2 
heterodimer was also explored. For this, a region spanning from the central domain (from Leu151 to 






arg337) to the C-terminal domain (from Val338 to Iso506) was selected for docking. We found 
favorable docked poses with predictive binding energies ranging from -5.8 to -5.0 kcal mol-1 (Fig. 43). 
 
 
In many of the predicted binding poses of the IVcore fragment, the phosphate and hydroxyl groups 
were interacting with the backbone of TLR2, including residues His398, Ser425, Lys422, Gln396, 
Lys347, Asn345, Asp286 and Asn257 (Fig. 43A). Moreover, hydrogen bonds stablished with TLR4 
residues Ser415, Gly389 and Lys388 were observed as well. The saccharide core from E. coli LPS was 
also docked in this region. The docked poses obtained, with predictive binding energies ranging from 
-5.5 to -5.2 kcal mol-1, indicate that E. coli core can theoretically interact with the TLR2 C-terminal 
domain (Fig. 43B), in an energetically favorable manner. The core also established hydrogen bonds 
with TLR4 Ser415, Lys388 similarly to O. intermedium LPS core, however it showed fewer hydrogen 
interactions with TLR2 residues (His398, Gln396 and Asn345). These data indicate that the IVcore 
fragment has a higher probability of interacting with more TLR2 residues, located in the central and 
C-terminal domains. Therefore, O. intermedium LPS core is more favorable to establish interactions 
with TLR2 interface compared to E. coli LPS core. 
  
A B 
Fig. 43 Docking of IVcore fragment in hTLR2 central and C-terminal domain in the hTLR2/TLR4/MD-2 complex  
A) Hydrogen interactions of IV core fragment with hTLR2 (green sticks) and hTLR4 residues (orange sticks). B) Hydrogen 





4.3.2.2 Docking with the model hTLR2 monomer 
TLR2 is described to associate with TLR1 or TLR6 receptors and this is required for recognition of 
the tri- and di-acylated lipopeptides, respectively (Alexopoulou et al., 2001; Buwitt-Beckmann et al., 
2006; Takeuchi et al., 2001; Takeuchi et al., 2002). TLR2 contains an internal hydrophobic pocket 
located in the convex region formed at the border of the TLR2 central domain (from Leu151 to arg337) 
and C-terminal domain (from Val338 to Iso506), where it accommodates two lipid chains from TLR2-
specific lipopeptides (Jin et al., 2007). Since TLR2 can hypothetically interact with TLR4 by O. 
intermedium LPS, docking studies were carried out using this LPS fragments in a region that covers 
the TLR2 pocket. Fragments IV19, IV28 and IVcore were docked in TLR2 pocket of the hTLR2 
monomer model (Fig. 44). Docked poses with favorable predictive binding energies were found 
(ranging from -7.8 to -6.6 kcal mol-1, from -6.9 to -6.5 kcal mol-1 and -5.7 to -4.9 kcal mol-1 for IV19, 
IV28 and IV core respectively). 
 
 
IV19 fragment docked in the TLR2 pocket showed the two fatty acid chains C19 and C18 buried in 
the pocket and the C14 chain was displayed in the solvent. On the other hand, IV28 fragment that 
comprises the large 28C chain was fully accommodated inside the pocket, whereas the C12 and C16 
chain protruded out of the TLR2 pocket. Regarding the IV core, the obtained docked poses were 
interacting with TLR2, near to its pocket. Thus, the docking calculation showed that the lipid A 
component of O. intermedium LPS is theoretically able to interact with the hydrophobic TLR2 pocket, 
comprising a maximum of two acyl chains. This is consistent with the reported triacylated lipopeptide 
binding in the hTLR2/TLR1 receptor (Jin et al., 2007).   
Fig. 44 Docking of the fragments IV19 (cyan), IV28 (magenta) and IVcore (yellow) in the hTLR2 pocket (TLR2 surface is 





4.3.2.3 Redocking of O. intermedium LPS core in the hTLR2/TLR4/MD-2 complex, in 
the presence of LPS in the MD-2 pocket 
O. intermedium LPS core is theoretically able to interact with hTLR2 monomer, near its pocket.  
Therefore, a redocking of the IV core fragment in the presence of an O. intermedium LPS in the MD-
2 pocket was performed.  The docked region covered the TLR4-TLR2 interface and TLR2 central and 
N-terminal domains (Fig. 45A). Favorable docked poses were obtained with binding energies ranging 
from -6.0 to -6.6 kcal mol-1. In this redocking, most of the docked poses were observed in TLR2-TLR4 
interface, in the presence of an LPS in the MD-2 pocket. The next step was to perform a redocking of 
the O. intermedium lipid A in the same region, in the presence of the core and the LPS molecule in the 
MD-2 pocket (Fig. 45B). Favorable docked poses for the lipid A fragment were found, with binding 
energies ranging from -5.9 to -5.2 kcal mol-1. This redocking showed that only C28 or C19 chain can 
be accommodated in the TLR2 pocket. Moreover, the lipid A backbone is near to the sugar KDO I of 
the core. Thus, these redockings indicate that, in the presence of an O. intermedium LPS molecule in 
the MD-2 pocket, the core and the lipid A can theoretically bind to the hTLR2 interface, in the 
hTLR2/TLR4/MD-2 heterodimer. However, the lipid A is capable of accommodating only one FA 




Fig. 45 A) Upper view IVcore (in magenta) redocked poses in the hTLR2 interface, in the presence of an O. intermedium 
LPS molecule (in cyan) in the MD-2 pocket. B) Redocking of the lipid A fragment (in purple) in the hTLR2 interface, in the 
presence of the IV core fragment and the O. intermedium LPS molecule in the MD-2 pocket (TLR2 represented in green and 





4.3.3 O. intermedium LPS induces hTLR4/MD-2 and hTLR2 heterodimerization 
As receptor dimerization appears to be required for PAMPs recognition and TLRs activation, 
fluorescence resonance energy transfer (FRET) was performed to evaluate the intermolecular distance 
between TLR4 and TLR2 in the presence of O. intermedium LPS. HEK293 stably expressing MD-2 
and CD14 were transiently transfected with TLR4-YFP (acceptor) and TLR2-CFP (donor) constructs 
and imaged in vivo. Unstimulated co-transfected cells showed a small FRET signal, with minute 




Fig. 46 O. intermedium LPS induces hTLR4-MD2 and hTLR2 heterodimerization.  
HEK293T were transiently transfected with the plasmids TLR4-YFP (acceptor) and TLR2-CFP (donor). After transfection, 
cells were left unstimulated or were stimulated with O. intermedium LPS (1µg/mL). FRET between YFP and CFP was 
measured in in vivo cells, by sensitized emission fluorescence. Corrected FRET images (FRET eff) are displayed using 
quantitative pseudocolor (right column). The graphics represent the quantification of FRET positive structures per total cell 
number, as well, as the area and mean fluorescence intensity of each punctate structure. The results are shown as mean ± 





After stimulation with O. intermedium LPS, a significant FRET signal was observed by the presence 
of more punctate structures and with higher fluorescence intensity. A tandem vector construct of CFP 
and YFP was used as a positive control, with a FRET efficiency of around 40% (data not shown). The 
size of these punctate structures however did not change upon cell stimulation. These results 
demonstrate that in resting cells, TLR4 and TLR2 receptors are closer from each other but not 
sufficiently to induce downstream signaling activation. However, O.intermedium LPS stimulation 
promotes a closer interaction between TLR4 and TLR2 receptors that enables the activation of 
downstream intracellular signaling events. Thus, these data indicate that this particular LPS from 

























5.1 TLR4 and TLR2 differential kinetics 
Our results show that stimulation of macrophages with TLR4 or TLR2 ligands resulted in striking 
differences in cytokine production. Specifically, TLR2/6 and TLR2/1 ligands exhibit a higher 
induction of anti-inflammatory mediators, such as IL-10 and ARG1, whereas TLR4 favors the 
expression of pro-inflammatory cytokines such as TNF-α, IL-12, IL-6 and iNOS (see Fig. 1 and 2). 
The higher IL-10/IL-12 ratios observed in macrophages activated by TLR2 ligands suggest a change 
to a M2 and regulatory phenotype, whereas LPS induces a M1-type macrophage as previously 
described. This is concordant with previous published data in human DCs stimulated with LPS, PGN, 
zymosan and Pam3Cys, where TLR2 ligands favored a Th2 response in contrast to LPS (Agrawal et 
al., 2003; Dillon et al., 2006; Re and Strominger, 2001).  
In this regard, several pathogens, such as Brucella abortus, Candida albicans or Mycobacterium 
tuberculosis may explore TLR2-mediated IL-10 induction as an virulence mechanism to induce M2 
macrophages and suppress Th1 response against the pathogen (Netea et al., 2004; Richardson et al., 
2015). Given this distinct cytokine profile, it was questionable if TLR4 and TLR2 ligands could 
activate exactly similar signaling pathways, including the activation of NF-κB and MAPKs p38 and 
ERK. Our results demonstrate different kinetics of activation between TLR4 and TLR2 ligands, 
however Pam3CSK4 and FSL-1 show similar kinetics of activation (see Fig. 3), which is in accordance 
with previous studies (Long et al., 2009). Our experiments were also performed in peritoneal 
macrophages, thus showing that this differential kinetics signaling occurs in both macrophage cell line 
and primary macrophages. Our work focused on the MAPKs ERK and p38 because they have a central 
role in activating and regulating a range of cellular responses. In macrophages, ERK and p38 are 
determinant in eliciting inflammatory responses through activation of nuclear transcription factors and 
through the stabilization and translation of cytokines mRNA that contain AU-rich elements. ERK is 
important for the induction of TNF-α, IL1-β, and IL-10, but negatively regulates IL-12 in response to 
LPS. On the other hand, p38 seems to be important in IL-12 induction and regulate TNF-α production 
at a posttranscriptional level. A possible explanation for the differential MAPKs activation by TLR4 
and TLR2 could be due to activation of different upstream activators of p38 and ERK. TAK1 is a 
general upstream kinase described to be important for activation of NF-κB, p38, JNK and ERK (Shim 
et al., 2005). Our results show that TLR4 and TLR2 ligands are dependent of TAK1 to induce ERK 
and p38 and this is observed for the Raw264.7 cell line as well as for peritoneal macrophages (see Fig. 
6). In most described cases, MEK1/2 is an upstream mediator of ERK1/2. Cell treatment with MEK1/2 
inhibitor gave a different response. Raw264.7 cells treated with PD98059 or with U0126 still induced 





marrow-derived macrophages (see Fig 7,9, 10 and 11). Thus, Raw264.7 cells can induce ERK by TLR2 
ligands stimulation in a mechanism independent of MEK1/2. This uncoupling phenomenon was 
observed in previous studies, showing that TNF-α or LPS-stimulated human neutrophils or PBMCs 
induced ERK in a MEK independent mechanism (Foreback et al., 1998; Simard et al., 2015). 
Therefore, MEK-independent ERK activation appears to be cell-type specific and limited to certain 
kind of stimuli. Given this, the question of which kinases were activating ERK independently of MEK 
in Raw264.7 cells was explored.  Several pathways have been reported to contribute for ERK activation 
in distinct cells systems and in response to different stimuli. These include Ras/Raf, a cascade usually 
activated by growth factors and cytokine receptors, PI3K-mTOR, TPL2 and classes of PKCs (Grammer 
and Blenis, 1997; Pathak et al., 2004; Shaul and Seger, 2007). Inhibitors of PI3K (wortmannin) and 
TPL2 (TPL2 inhibitor) were tested in Raw264.7 cells, however no effect was observed in ERK 
phosphorylation in response to TLR2 ligands (data not shown). Previous studies report that PKCζ 
inhibition was found to block MEK and ERK activation by LPS (Monick et al., 2000). This is in 
accordance with our results obtained in response to LPS, however a partial inhibition was observed for 
TLR2-mediated ERK phosphorylation. Nevertheless, treatment with Ras inhibitor (manumycin), not 
only impaired ERK activation by LPS, but also ERK phosphorylation mediated by Pam3CSK4 and 
FSL-1 (see Fig. 12). Thus, Ras, and in part PKCζ contribute to ERK activation in TLR2 ligands 
stimulated Raw264.7 cells, independently of MEK1/2.  
Although macrophage cell lines such as Raw264.7, have been widely used as a surrogate of primary 
macrophages for signaling studies, previous studies demonstrate that unstimulated Raw264.7 cells 
contain about 1400 genes, which are differentially expressed relative to primary macrophages. In 
particular, this cell line has been described have higher expression of genes associated with mitosis 
and DNA metabolism whereas primary macrophages show higher expression of genes related to 
defense response and antigen processing and presentation (Maurya et al., 2007). Raw264.7 cells are 
transformed macrophage-like cell line derived from the lymphoma of a BALB/c mouse infected by the 
Abelson murine leukemia virus (Raschke et al., 1978). Particularly, an oncogenic form of the Abelson 
kinase, vAbl, is constitutively expressed in these cells, leading to a constitutive activation of 
proliferation-related signaling pathways, one of them being Ras (Shore et al., 2002). These changes in 
signaling mediator’s activity should be taken into account when using macrophage-like cell lines as a 
validation model for signaling or infection studies performed in primary macrophages.  
Our results also demonstrate that Raw264.7 cells, but not peritoneal macrophages, induce p38 
phosphorylation by an alternative mechanism besides the classical MEKK3/6 axis, and is based on 
autophosphorylation (see Fig 13 and 14). However, this phenomenon occurred in response to LPS and 
Pam3CSK4, but not for FSL-1. As it was mentioned before, SB203580 inhibits p38 catalytic activity 
targeting p38α and p38β isoforms. By inhibiting p38 with SB203580, Ge et al. demonstrated that a 
TAB1-mediated p38α autophosphorylation mechanism occurs in response to bacterial components 





that p38β has the capacity for autophosphorylation through spontaneous catalytic activity, triggered 
and regulated by MAPK insert and C-terminal motifs present in this isoform (Beenstock 2014). 
Moreover, autoactivation of p38α is also promoted in T cells (Salvador et al., 2005). Altogether, this 
data suggests that p38 autophosphorylation occurs in certain cell types and depends on the initial 
stimulus. This is in accordance with our results, where LPS-stimulated Raw264.7 cells activated p38 
through this mechanism, and at a lesser extent in response to TLR2 ligands. Furthermore, this 
phenomenon was not observed in peritoneal macrophages. Indeed, a similar phenomenon was found 
by infecting bone marrow-derived macrophages with the parasite Toxoplasma gondii, which triggered 
TAB1-p38α autophosphorylation, but not LPS (Kim et al., 2005). Immune cells have developed 
distinct modes for p38 activation, one of them in the absence of MKK3/6 activation, probably to 
activate p38α and p38β isoforms rather than other isoforms. Therefore, our results elucidate that Raw 
264.7 macrophage cell line use distinct and MEK-independent upstream activators for TLR2-mediated 
ERK activation as well as a p38 autophosphorylation mechanism for its activation, which is not 
observed in primary macrophages.  
The TLR4 and TLR2 differential kinetics on ERK and p38 activation that we observed in macrophages 
cannot be ascribed to the differences on the signaling pathways activation that we tested. A plausible 
explanation for these kinetic activation differences could be the different recruitment of MyD88 and 
Mal/TIRAP adaptors to TLR2 and TLR4 receptor TIR domains, the termed TLR signalosome. TLR4 
signalosome is formed by the recruitment of two Mal dimers that in turn recruit four MyD88-dimers. 
Then other six MyD88 molecules bind to this cluster, allowing IRAK4 and IRAK2 bind and initiate 
the signaling cascade (Guven-Maiorov et al., 2015). It turns out TLR2/6 and TLR2/1 heterodimers 
induce a different signalosome composition, where TLR2/1 binds a TIRAP and MyD88, and TLR2/6 
recruits two TIRAP molecules. Additionally, three MyD88 molecules are recruited to the primary 
cluster, which are less that then the ones recruited by TLR4 (Piao et al., 2016). Therefore, the different 
composition and stoichiometry of MyD88 and TIRAP complexes in TLR4 and TLR2 heterodimers, 
can likely contribute for the different kinetics of NF-κB and MAPKs activation by TLR4 and TLR2 
ligands.  
Dephosphorylation of MAPKs is likely to be one of the most efficient mechanisms to control their 
activation. Dual specificity phosphatases (DUSP), also termed MKP can negatively regulate MAPKs 
activation through dephosphorylation of phosphotyrosine and phosphothreonine residues. DUSPs can 
be induced by TLR-mediated activation of MAPKs, creating a negative feedback loop to limit MAPKs 
activation. Among DUSPs, MKP-1 is highly expressed in macrophages. Our results show that TLR4 
and TLR2 ligands induce MKP-1, however with different kinetics of activation (see Fig. 15A and B), 
similarly to ERK and p38 MAPKs. It is likely that this spatiotemporal difference in MKP-1 induction 
via TLR4 and TLR2 ligands is due to the same differences observed in ERK and p38 induction.  
Interestingly, MKP-1 mRNA levels induced by TLR2 ligands decay completely after 2 hours, whereas 





protein expression, however, since MKP-1 is likely stabilized, the decay levels are observed at 4 hours 
after TLR2 stimulation (see Fig 15C and D). Therefore, the duration of MKP1 activation and 
stabilization is longer by TLR4 activation but shorter by TLR2. Distinct upstream mediators are likely 
contributing and regulating MKP1 expression. Indeed, MKP-1 can be induced and stabilized by ERK 
in LPS-stimulated Raw264.7 cells, and bone marrow-derived macrophages (Crowell et al., 2014). Our 
data shows that inhibition of ERK in Raw264.7 cells impairs MKP-1 induction by TLR4 and for TLR2 
ligands, being more evident for FSL-1, whereas p38 inhibition only affected MKP-1 levels upon 
stimulation by LPS (see Fig 16A). These results are in accordance with previous published work, where 
LPS stimulated-Raw264.7 cells induce MKP-1 primarily by ERK and at a lesser extent by p38 (Chen 
et al., 2002). In addition, when using peritoneal macrophages, our results gave an ERK and p38-
dependency for full MKP-1 induction for the distinct ligands (see Fig. 16B). Hu et al reported a similar 
conclusion using the same cell type, but stimulating with LPS and PGN, and found a p38-MK2 
regulation feedback, through MKP-1 induction (Hu et al., 2007). However, there are conflicting 
reported results regarding MKP-1 induction in primary macrophages. Published data shows that JNK 
is required for MKP-1 induction in bone marrow-derived macrophages, in response to LPS or M-CSF 
(Sanchez-Tillo et al., 2007). However, in this study, BALB/c mice macrophages were used. Other 
study points that MKP-1 is induced by the kinases MSK1/2, which are downstream targets of ERK and 
p38 (Ananieva et al., 2008). Therefore, ERK, p38 and JNK drive MKP-1 induction, however the 
contribution of each MAPK seems to depend on the mice genetic background, cell type and stimuli. 
MKP-1 induction is determinant for controlling the length of MAPK responses in macrophages. 
Previous studies demonstrated that MKP-1 KO peritoneal, alveolar macrophages and bone marrow-
derived macrophages showed prolonged activation of p38 and JNK, suggesting that MKP-1 regulates 
primarily p38 and JNK, but has little effect on ERK, in response to LPS (Chi et al., 2006; Hammer et 
al., 2006; Zhao et al., 2005). Our results show a similar result in response to the TLR2 ligand FSL-1, 
where MKP-1 KO PM exhibit a prolonged p38 phosphorylation whereas ERK phosphorylation was 
not affected (see Fig. 17). In the absence of MKP-1, p38 is likely to eventually become inactivated by 
other MKPs, though at a much slower rate. This is consistent with the observation that deactivation of 
p38 in MKP-1 KO macrophages was delayed. Overall, MKP-1 has a central role in the regulation of 
p38.  
MKP-1 was previously described to regulate pro and anti-inflammatory cytokines in response to LPS 
stimulation (Chi et al., 2006). We addressed the role of MKP-1 in the inflammatory response mediated 
by TLR2 ligands. Using MKP-1 KO PM, our data shows that this phosphatase contributes to the 
induction of pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α, but regulates IL-10 
expression at later time points (8 and 24h), whereas at 4 hours of stimulation, cytokine levels are similar 
to WT cells (see Fig. 18). MKP-1 regulation, however, is stronger for TLR2 ligands in comparison to 
TLR4. In contrast, Salojin et al reported that MKP-1 KO BMDM not only exhibit an increase in TNF-





2006). However, Chi et al demonstrates that MKP-1 BMDM deficient macrophages induce more IL-
10, observed for different stimuli such as PGN and Pam3CSK4, which are more in accordance with 
our results. This induction was blocked by a p38 inhibitor, showing that p38 mediates IL-10 synthesis 
(Chi et al., 2006). In our hands, TNF-α levels were enhanced in MKP-1 KO cells at earlier time points, 
but at later stages, no differences were observed comparing with WT cells. On the other hand, Zhao et 
al also observed that MKP-1 KO PM prolonged p38 activation and leads to augmented production of 
TNF-α, IL-6, and IL-10, however, IL-12 is downregulated. This was observed at 6 and 24 hours after 
LPS stimulation (Zhao et al., 2006). Together with our results, MKP1 regulates pro and anti-
inflammatory cytokines, likely by downregulation of p38 activity. In addition, we demonstrate MKP-
1 is important for pro-inflammatory cytokine’s production in response to TLR2 ligands. Nevertheless, 
the outcome of MKP1 regulation in cytokine’s expression seems to depend on the cell type, the stimuli 
and the stage where inflammation is being analyzed. 
Our results also demonstrate that p38 is critical for later anti-inflammatory IL-10 induction but not for 
pro-inflammatory cytokines, regardless of the stimuli (see Fig. 20). This is in accordance with Chi et 
al, which demonstrates that IL-10 induction mediated by LPS was blocked by a p38 inhibitor, implying 
that p38 mediates IL-10 synthesis (Chi et al., 2006). Our results demonstrate that TLR2 ligands also 
induce IL-10 expression fully dependent of p38 at later stages. The higher levels of IL-10 expression 
could be due to the early activation of p38 by these ligands, in contrast with LPS. Furthermore, it is 
described that IL-10 inhibits the transcription of pro-inflammatory cytokines via IL10R-Janus kinase-
Fig 1D. Model Hypothetical model of the molecular events leading to high IL-10 levels in response to TLR2 ligands. 
TLR2 ligands such as Pam3CSK4 or FSL-1 activate NF-κB, ERK and p38 earlier and faster (≈ 3 min) compared to LPS (≈ 
30 min), allowing a faster induction of cytokines such as TNF-α, mediated by NF-κB and IL-12, IL-6 and IL-10 by ERK. The 
earlier induction of MKP-1 by TLR2 activation contributes for upregulation of pro-inflammatory cytokines and MKP-1 can 
dephosphorylate 38. On the other hand, the early TLR2-mediated p38 induction contributes for later and high IL-10 levels of 
expression. Consequently, IL-10 activates the STAT3 pathway which amplifies IL-10 production and regulates pro-





STAT3 pathway (Murray, 2006). Therefore, the earlier activation of this pathway could contribute for 
the higher IL-10 levels and lower pro-inflammatory cytokines observed via TLR2 activation at later 
stages (Fig. D1).  
The transcription factors also influence cytokine expression. SP1, c/EBPβ. CREB/AP1 and MAF have 
been shown to bind to IL-10 promoter. MSK1/MSK2-mediated activation of CREB and ATF1 induced 
IL-10 in response to LPS. However, the different stimuli may induce different transcription factors 
activated in a same cell type. For example, p38 induce IL-10 promoter via SP1 in response to LPS, 
whereas c/EBP5 was found to be recruited in response to cAMP (Brenner et al., 2003; Ma et al., 2001). 
Further studies are required to identify the downstream targets of p38 that mediate IL-10 regulation in 







5.2 TRIF-IFN-β signaling dependence in TLR2 inflammatory responses and Listeria 
infection 
Similar to TLR4 and endosomal TLRs, it was recently found that TLR2 activation induces not only 
inflammatory cytokines but also type I IFNs. Thus, Dietrich et al. observed that TLR2 ligands induced 
IFN-β mediated by MyD88- IRF1 and IRF7 mechanism in macrophages (Dietrich et al., 2010). 
Furthermore, this TLR2 signaling occurs in endosomes, similar to other TLRs. So far, these results 
were observed only in BMDMs. We evaluated TLR2-mediated IFN-β production in peritoneal 
macrophages and the Raw264.7 cell line, observing that TLR2 ligands induce IFN-β although at lower 
levels than TLR4 ligands (see Fig. 21). This is consistent with the reported studies performed in 
BMDMs. Moreover, IFN-β induction in response to TLR2 ligands was dependent of the receptor 
endocytosis in peritoneal macrophages, demonstrating that distinct macrophage types require TLR2 
internalization to induce IFN-β (see Fig. 22). Indeed, Pam3CSK4 and FSL-1 rapidly triggered TLR2 
internalization, however to a lesser extent compared to LPS-stimulated TLR4 internalization.  
Our results further show that TLR2 ligands induce IRF3 and IRF7 activation in peritoneal macrophages 
earlier compared to LPS and mediated by endocytosis (see Fig. 24 and 25). On the other hand, LPS-
stimulated BMDMs displayed IRF3 and IRF7 phosphorylation. In this cell type, Pam3CSK4 failed in 
activating IRF3, whereas IRF7 was phosphorylated in response to both TLR2 ligands, Pam3CSK4 and 
FSL-1 (see Fig. 26). Published data demonstrated BMDMs deficient in IRF1 and IRF7, but not IRF3, 
failed in producing IFN-β mediated by TLR2 ligands, demonstrating that IRF3 is dispensable for IFN-
β production in these macrophages (Dietrich et al., 2010). Our results support that the ligand 
Pam3CSK4 weakly activates IRF3 in BMDMs. Previous studies reported that IRF3 and IRF7 are 
activated in response to vaccinia virus (Barbalat et al., 2009; Dietrich et al., 2010). Moreover, both 
IRF1 and IRF2 had a role on TLR2-dependent-IFN production in Raw264.7 cells (Liljeroos et al., 
2008). Therefore, it is feasible that IFN-β activation is controlled by different IRFs, which depend on 
the initial stimulus or type of microbe and cell type. 
It is well characterized the TLR4 dependence in TRIF signaling for type I IFN induction. We 
demonstrated that TLR2 activation requires TRIF signaling in part, to induce IFN-β. Indeed, IFN-β 
production is only slightly affected in TRIF deficient cells after TLR2 stimulation for 3 hours. 
However, at 6 hours, a stronger TRIF dependency for IFN-β production is observed, mainly in response 
to FSL-1 (see Fig. 27). Our results are in accordance with Stack et al, which demonstrated a strong 
dependency of MyD88 for Pam3CSK4-mediated IFN-β production (Stack et al., 2014). Indeed, Stack 
et al demonstrated an endosomal localization of TLR2, TRAM, Mal and MyD88 within 20 min after 
TLR2 ligands stimulation, whereas Nilsen et al implied that TLR2 is recruited and co-localized with 
TRAM and TRIF upon stimulation with FSL-1 for 1 hour (Nilsen et al., 2015). Thus, in addition to the 
previous findings, our results support that in contrast to TLR4, TLR2 is rapidly internalized, likely 





required to induce the second wave of IFN-β. Given the TRIF-signaling dependency for TLR2-
mediated IFN-β induction, we also observed that TLR2 can utilize this pathway to induce a specific 
set of cytokines. Our results show that TNF-α and IL-12p40 induction are strongly dependent of TRIF 
and IFN-β at later stages, whereas the anti-inflammatory cytokine IL-10 is not affected (see Fig. 28 
and 29).  
 
Indeed, this is in accordance with our results, showing that IL-10 induction is dependent of the MAPK 
p38 (see Fig. 19 and 20). Moreover, MyD88 and TRIF dependency for TLR2-mediated Ccl5 and Ccl4 
chemokines was previously reported in peritoneal macrophages (Nilsen et al., 2015). Thus, it feasible 
that both TRIF and MyD88 pathways mediate TLR2-induced TNF-α and IL-12 expression in 
macrophages, which may be necessary to mount optimal host inflammatory responses towards certain 
infections (Fig. D2). 
Fig. D2 Proposed model for TRIF signaling contribution to TLR2-mediate inflammatory responses in macrophages. 
In an initial phase, TLR2 ligands recruit MyD88 and Mal adaptors to activate the transcription factors NF-κB and the MAPKs 
ERK and p38. NF-қ and ERK contribute for the first wave of pro-inflammatory cytokines and p38 is determinant for IL-10 
induction. Upon TLR2 stimulation, a fast internalization of this receptor occurs, either complexed with MyD88 or by 
recruiting MyD88 in endosomes. This signaling promotes the activation of the transcription factors IRF1 and IRF7, which 
contribute for IFN-β transcription at earlier time points (3h). Once in the endosomes, TLR2 recruits TRIF adaptor. The 
activation of these pathways induces IRF3 and IRF7, which in turns promote IFN-β at later time points (6 h). The expressed 
IFN-β activates IFN receptor and downstream signaling pathways are activated in order to induce pro-inflammatory 





Bacteria such as Lactobacillus acidophilus, Staphylococcus aureus, Borrelia burgdorferi and 
Legionella pneumophila have been found to trigger type I IFN production in a TLR2-dependent 
manner in the host (Liljeroos et al., 2008; Opitz et al., 2006; Petnicki-Ocwieja et al., 2013; Weiss et 
al., 2010). Therefore, type I IFNs appear to play a key role as immunomodulatory cytokines capable 
of enhancing protective immune responses during bacterial infections. However, different roles of type 
I IFN during Listeria monocytogenes infection were suggested. Initial studies showed that type I IFN 
production is harmful to the host in Listeria monocytogenes infection. IFNAR1 KO mice were found 
to be resistant to L. monocytogenes infection (O'Connell et al., 2004) and the mechanism attributed to 
this resistance was a reduced lymphocyte and macrophage apoptosis mediated by type I IFNs, 
sensitizing these cells to bacteria invasion (Carrero et al., 2004). However, recent investigations 
suggest that these results depend greatly on the route of infection (Kernbauer et al., 2013; Pitts et al., 
2016). Moreover, the timing of type I IFN production by the host is likely to be determinant for the 
beneficial and protective role of this mediators during Listeria infection (Pontiroli et al., 2012).   
Neonatal listeriosis represents between 16 and 27% of invasive listeriosis cases and is associated to 
high mortality rates (20-60%). In addition, neonates commonly develop symptoms of septicemia and 
meningitis. Pregnancy increases the susceptibility to L. monocytogenes infection since placental-
derived Th1 antagonistic cytokines confer a Th2 type response in the fetus. Thus, suppression of Th1 
responses is advantageous for survival of the fetus but increases the newborn susceptibility to 
infections. Neonates have an immature immune system, associated with a downregulation of Th1-
dependent anti-microbial immunity. Indeed, neonatal macrophages are defective in the secretion of 
Th1-type cytokines such as IL-12, IFN-γ, TNF-α, IL-6, and show a low degree in TLRs expression 
compared to adult macrophages.  Consequently, induction of cytotoxic T cells is compromised, 
rendering neonates more susceptible to Listeria infections (Marodi, 2006). In view of previous 
published data, TLR2 appears to be important for recognition of L. monocytogenes during in vivo 
infection (Boneca et al., 2007). Moreover, our results together with published data supports that TLR2 
signaling induces IFN-β, mediated by endocytosis (Dietrich et al., 2010; Torres et al., 2004). In 
addition, IFN-β shows protective effects against Listeria infection when administered in the initial 
phase of bacteria challenge (Pontiroli et al., 2012). Therefore, we prompted to explore the in vivo effect 
of TLR2 ligands in the prevention of neonatal listeriosis.  
The experimental murine model of neonatal listeriosis can mimic several human clinical symptoms of 
listeriosis. The number of neonates from infected mothers is reduced compared to non-infected 
mothers, which resembles spontaneous abortion or stillbirth (Calderon-Gonzalez et al., 2017). Our 
results show a reduced number of neonates from infected mothers compared to FSL-1-treated mothers, 
but not significant. However, neonates from infected mothers presented impaired coordinated 
movements and lesser brain integrity compared to neonates from treated mothers (see Fig. 31). These 
symptoms are related with brain dysfunction and resemble severe brain disease. Moreover, lack of skin 





the epidermis (Bronchalo-Vicente et al., 2015). Our results show that skin spots lacking pigmentation 
were observed in infected neonates but not in treated neonates. In addition, FSL-1-treated mothers 
presented a uterus with less fetal resorptions compared to infected non-treated mothers. These results 
indicate that FSL-1 attenuates neonate brain disease symptoms and reduces the chance of fetal loss 
during pregnancy. Moreover, FSL-1 treatment reduced in some extent the bacterial growth in the liver 
and spleen of infected mothers, however the effect was more evident in infected neonates’ brain, with 
100-fold reduction in bacteria load (see Fig. 32). It is likely that a stronger regulation of bacterial 
growth is observed in the brain due to the lower bacterial load compared to the liver and spleen. On 
the other hand, in intravenously bacteria injection, all the inoculum enters as a bolus into the 
bloodstream and almost all bacteria deposited in the liver and spleen within 15 min (Gregory et al., 
1996). Moreover, FSL-1 administration was performed at the same time of Listeria challenge, which 
could explain the weak effect of FSL-1 in bacterial burden reduction in primary targeting organs. 
Nevertheless, the FSL-1 role in the reduction of bacterial load in neonates’ brain is likely related with 
the higher levels of IFN-β observed in infected and treated neonates’ microglia. Ponteroli et al observed 
an increment of IFN-γ production by NK cells and reduced bacterial burden when treated with 
exogenous IFN-β during early infection (Pontiroli et al., 2012). It is feasible that IFN-β induction 
mediated by FSL-1 treatment in early infection stage determines the protective effect in reducing the 
bacterial growth in the brain. In addition, infected and FSL1- treated mothers presented higher levels 
of MCP-1 and slightly higher levels of TNF-α in the serum, whereas IL-10 and IL-6 levels were not 
altered (see Fig. 33). Secreted TNF-α is determinant for neutrophils and NK cells activation and MCP-
1 chemokine is secreted by neutrophils to recruit macrophages to the sites of infection (Zenewicz and 
Shen, 2007). Therefore, FSL-1 treatment likely modulated the immune system of infected mothers to 
induce TNF-α over Th2 cytokines (IL-6 and IL-10) and the recruitment of phagocytic cells. Our results 
further indicate that Listeria-infected dendritic cells exhibited higher levels of TNF-α, IL-6 and IL-12 
as well as increased IFN-β levels upon treatment with Pam3CSK4 and FSL-1 compared to infected 
non-treated cells (see Fig. 34A). DCs are determinant to bridge innate and adaptive immunity. In 
response to Listeria, this antigen-presenting cells stimulate specific types of T cells and, DCs prime 
CD4+ T and CD8+ T cells for bacteria killing and to mount a proper memory T cell population. 
Treatment with TLR2 ligands increments Th1 cytokines in infected DCs but maintains IL-10 levels, 
thus exerting a Th1/Th2 balance. Moreover, treatment with exogenous IFN-β increased pro-
inflammatory cytokines but decreased IL-10 in a dose dependent manner (see Fig. 34B). These results 
show the modulatory role of IFN-β in cytokines during the bacterial infection. Furthermore, TLR2-
induced TNF-α and IL-6 were partially impaired by neutralizing IFN-β activity and IL-12 was fully 
inhibited in infected DCs (see Fig. 35). This data demonstrates that TLR2 ligands can modulate 
cytokine levels, in Listeria-infected cells, eliciting IL-6, TNF-α and IL-12 expression, mediated by 
IFN-β. Therefore, TLR2 ligands induce a tuned immunomodulatory effect, with proper IFN-β and pro-





studies with TLR2 ligands in this model of Listeriosis are necessary to better elucidate the beneficial 
effects of these ligands in controlling the pathogen dissemination in the brain, and the mechanisms 






5.3 Ochrobactrum intermedium LPS induces TLR4 and TLR2 heterodimerization  
TLR4 is considered the major receptor involved in the recognition of all LPS. However, this 
paradigm is being questioned and debated. Despite the general structure, lipidA, Core and O-
saccharide repeats, LPS from Gram-bacteria have many different compositions in those 3 
parts. Previous data reported that LPSs from Legionella pneumofila, Rhizobium species or 
Porphyromonas gingivalis require TLR2 rather than TLR4 to elicit innate immune responses 
(Darveau et al., 2004; Girard et al., 2003; Hirschfeld et al., 2001; Werts et al., 2001). 
Nonetheless, this is a debated issue since a recent publication, demonstrates that pure 
Porphyromonas gingivalis LPS activity is mediated exclusively through TLR4. A possible 
explanation for all those discrepancies is contamination from other cell wall components. 
Thus, the standard purified Porphyromonas gingivalis LPS can be contaminated by 
lipoproteins that bind TLR2 that can explain these controversial results. Nevertheless, purity 
may not be the full explanation since those above mentioned LPSs present a structure and 
composition very different from the enterobacterial LPSs, the archetypical TLR4 ligand. One 
of the common features is the presence of very long fatty acid chains in the lipid A that reduce 
the affinity of the LPS. Members of α-Proteobacteria such as Brucella and Ochrobactrum also 
express these atypical LPSs, comprising at least two very long FA chains, a disaccharide 
backbone and core saccharide and O-antigen with distinct sugars and, importantly, different 
net charge compared with the classical E. coli LPS. It is evident that the peculiar structure of 
those LPSs confers to this class of bacteria a stealthy strategy for immune system recognition.  
 Indeed, our results show that the response by Ochrobactrum intermedium LPS requires higher 
concentrations to induce similar cytokine levels or signaling activation compared to E. coli 
LPS (see Fig. 36). Moreover, O. intermedium LPS induces inflammatory responses mediated 
not only by TLR4 but also by TLR2, as shown by the experiments with TLR deficient 
macrophages (Ovejero Guisasola, 2012). This TLR2-dependence is contradicting the current 
dogma that LPS molecules are strictly recognized by TLR4/MD-2 homodimers. Our FRET 
analysis indicates that O. intermedium LPS potentiates the association of TLR4/MD-2 and 
TLR2 in vivo (see Fig. 46). Indeed, our molecular dockings analysis contribute to elucidate 
the predictive interaction of O. intermedium LPS with TLR4/MD-2 homodimers, where the 
O. intermedium LPS is displaced from MD2- pocket and the core saccharide is diving towards 
the interface of the complex (see Fig. 40). Moreover, determinant interactions with TLR4 (e.g. 
Tyr296, Asp294 and Arg264) and TLR4* residues (Gln436) are lost. This implies that O. 
intermedium LPS impairs the formation of stable TLR4/MD-2 homodimers. On the other 
hand, the docking of this LPS in a putative TLR2/TLR4 MD-2 heterodimer demonstrated that 





determinant interaction with TLR4 (Tyr 296 and Arg 264) and the O-antigen portion seems to 
be determinant for the interaction with TLR2 (see Fig. 41). Therefore, O. intermedium LPS is 
likely to favor the formation of TLR2/TLR4/MD-2 heterodimers rather than TLR4/MD-2 
homodimers. Nonetheless, our FRET results demonstrate that interaction of TLR2 and TLR4 
is somehow weak (5-10 nm). The weak contact between TIR domains of the dimers may 
impair the recruitment of downstream adaptors and consequently leading to a poor activation 
of signaling cascades. This could explain the very weak agonist activity by O. intermedium 
LPS.  
On the other hand, published studies demonstrate that a mutation in Brucella LPS core, leading 
to the specific removal of the side branch increased the inflammatory response compared to 
the Brucella WT LPS (Conde-Alvarez et al., 2012).  The core side branch is composed of 
positive charge GlcpN residues linked to a mannosyl residue. It is suggested that these positive 
charges neutralize the KDO groups and the phosphate groups of the diaminoglucose backbone, 
thus displacing the Brucella LPS from the MD-2 pocket (Fontana et al., 2016). It was proposed 
that the core saccharide and the peculiar long acyl chain of the lipid A of the Brucella LPS 
hampers its MD-2 recognition. So far, it is only considered that this leads to the impairment 
of TLR4/MD-2 dimerization. However, it is feasible that TLR4 can also stablish interaction 
with other receptors in response to this type of atypical LPSs, rendering a lower inflammatory 
response. We further compared the composition of the cores between Brucella abortus, O. 
Anthropi and O. intermedium to evaluate the differences in sugar composition and net charge 
(Fig. 3). Brucella core is composed of glucosamines, which confer a strong positive charge 
and displacement of the LPS from MD-2 pocket, thus hampering TLR4 activation. O. anthropi 
contains a similar composition, but only harbors one glucosamine on the core side branch and 
a negative GalpA residue linked to KDO II, which confers less positive net charge. 
Interestingly O. intermedium core contains the same side branch than O. anthropi, but the two 
residues are phosphorylated. This confers a more negative charge in the core compared to the 
O. anthropi core (Fig.3). Eventually, the less positive charge can lead to a lower displacement 
of the lipid A from MD-2, however this shift is likely to be less pronounced compared to E. 
coli lipid A. This could explain the findings from Barquero-Calvo et al., where O. anthropi 
triggers inflammatory responses lower than Salmonella enterica, but higher than Brucella 






An important aspect to consider is the LPS moieties existent in aqueous solvents since 
different species besides the full LPS may exist. Portions of the lipid A or the core saccharide 
can be present as well. Moreover, the O-antigen, which is known to serve as a “camouflage” 
for bacteria phagocytosis, may also be present in fragments.  Considering this, lipid A 
fragments as well as the core were docked in the interface of TLR2 heterodimerized with 
TLR4/MD-2 plus an LPS accommodated in MD-2. The core distributes in the interface of 
TLR2, whereas docked poses in a TLR2 monomer show that one fatty acid chain of the lipid 
A can be accommodated in the TLR2 pocket and the core can stablish interactions near the 
TLR2 pocket. A proposed model consists first in the dimerization step of TLR2 and 
TLR4/MD-2 monomers induced by full O. intermedium LPS binding in MD-2 pocket and 
consequently, LPS moieties can bind to TLR2 and likely contribute for the final dimerization 
process of both TLR2 and TLR4/MD-2. Therefore, our results have clearly pointed out to the 
possibility of previously undescribed TLR2/TLR4 heterodimers in response to a particular set 
of atypical LPSs, and the important role of the core structures in the binding besides the well-
known lipid A.  
Fig. 3 Structure model of Brucella, O. Anthropi and O. intermedium LPS core.  
The three LPSs carry a similar lipid A with two very long FA chains but different cores. Brucella LPS contains four 
glucosamines in the side branch of the core, whereas O. Anthropi LPS only have one residue. Moreover, O. Anthropi LPS 
contains a negatively charged GalpA in the core branch that links to the O-antigen portion. O. intermedium LPS contains one 
glucosamine and mannose on the side branch of the core but both are negatively charged. The table represents the net charge 





Bacteria have developed distinct mechanisms to escape and low the recognition by the immune 
system. The LPS number of acyl chains and the length greatly influence the endotoxicity of 
the LPS. On example is Yersinia pestis and Porphyromonas gengivalis, which express mainly 
hexaacylated LPS at 28ºC, however at 37 ºC (host temperature) the LPS is mostly in 
tetraacylated form, avoiding innate immune cell activation  (Kawahara et al., 2002; Knirel et 
al., 2005). In addition, the core saccharide and O-antigen composition and surface charge 
confer an efficient mechanism in masking the pathogen from host recognition. Brucella is an 
opportunistic pathogen usually found in immunocompromised patients. On the hand, 
although, Ochrobactrum is a living soil organism, it has been reported to display some degree 
of pathogenicity (Berg et al., 2005; Mahmood et al., 2000). Both bacteria, phylogenetically 
closed, are likely to share similar mechanistic strategies of host evasion. Brucella LPS weakly 
activates TLRs activation, impairing the induction of Th1 responses determinant for the 
bacteria clearance. Furthermore, most of the infectious diseases lack for efficient vaccines. 
This limitation comes from the incorrect use of adjuvants to induce an appropriate immune 
response. Moreover, the toxicity of the adjuvant in human vaccines formulation is another 
concern due to the exacerbated Th1 responses. Since the core saccharide, besides the VLFCAs, 
shows an impact in the induction of inflammatory mediators, the use of Brucella core mutants 
are being developed as adjuvants for vaccines (Conde-Alvarez et al., 2013). Our group 
previously characterized the potential use of O. intermedium LPS as an adjuvant for vaccines 
in immunocompromised and septic animals with no side toxicity (Ovejero Guisasola, 2012). 
Besides, the inflammation response induced by the O. intermedium LPS depend on TLR4 and 
TLR2 receptors. Given this, further studies are necessary to elucidate in a molecular and 
biological perspective the impact of the cores and O-antigen of these type of LPS for the 
























1. TLR2 ligands induce higher levels of anti-inflammatory IL-10 and lower levels of pro-inflammatory 
cytokines IL-12, TNF-α compared to TLR4 ligands. TLR2 ligands activate NF-ҡB and MAPKs earlier 
compared to TLR4 ligands. 
 
2. TLR2 ligands induce ERK by a MEK1/2-independent but Ras-dependent in the Raw264.7 cell line. 
Moreover, Raw264.7 cells induce p38 by an autophosphorylation mechanism only in response to 
TLR4. These phenomena were not observed in primary macrophages. 
 
3. MKP-1 controls p38 phosphorylation and differentially controls pro and anti-inflammatory 
cytokines in response to TLR2 activation. The early p38 is critical for the higher levels of IL-10 
induction in response to TLR2 ligands. 
 
4. TLR2 ligands induce IRF3, IRF7 and IFN-β in peritoneal macrophages in an endocytosis dependent 
manner. TRIF-IFNβ signaling contributes for later IL-12 cytokine expression in response to TLR2 
ligands. TLR2/6 ligand FSL-1 treatment in neonatal listeriosis confer a preventive effect on neonate’s 
brain disease, by decreasing bacteria load and increasing protective Th1 cytokines. TLR2 ligands 
treatment in Listeria-infected DC cells exert a Th1/Th2 balance, through an increase in IL-12 levels 
mediated by IFN-β. 
 
5. Ochrobactrum intermedium LPS induces a weaker inflammatory response mediated by TLR4 and 
TLR2 compared to the TLR4-dependent E. coli LPS, in primary macrophages. Ochrobactrum 







1. Los ligandos de TLR2, Pam3CSK4 (TLR2/TLR1) y FSL-1 (TLR2/TLR6) inducen niveles más 
elevados de la citoquina antiinflamatoria IL-10 and niveles más bajos de citoquinas proinflamatorias 
en comparación a los ligandos TLR4. Además, los ligandos TLR2 activan NF-κB y MAPKs más 
temprano que el LPS.  
 
2. Los ligandos TLR2 inducen la MAPK ERK por un mecanismo independiente de MEK1/2, pero 
dependiente de Ras en la línea celular Raw264.7. Este fenómeno no se observa en macrófagos 
primarios.  
 
3. MKP-1 controla la fosforilación de p38 y regula diferencialmente la expresión de citoquinas pro y 
antiinflamatorias por la activación de TLR2. La activación temprana de p38 es importante para los 
altos niveles de inducción de IL-10 en respuesta a los ligandos TLR2. 
 
4. Los ligandos TLR2 inducen IRF3, IRF7 y IFN-β en macrófagos peritoneales por un mecanismo 
dependiente de endocitosis. La ruta de señalización TRIF-IFN-β contribuye a la expresión de IL-12 
por la activación de TLR2. El tratamiento con el ligando FSL-1 en listeriosis neonatal tiene un efecto 
preventivo en la enfermedad cerebral de los neonatos, por disminución de la carga bacteriana y 
incremento de la expresión de citoquinas Th1 protectoras. Además, el tratamiento de células 
dendríticas infectadas con Listeria con los ligandos TLR2 incrementa los niveles de IL-12 mediado 
por IFN-β, creando un balance Th1/Th2. 
 
5. El LPS de Ochrobactrum intermedium induce un respuesta inflamatoria mas debil en comparacion 
al LPS de E coli, y dependiente de TLR4 y TLR2. O interermedium LPS favorece la dimerizacion de 
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